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      Résumé 
La technique du laser femtoseconde (fs) a été précédemment utilisée pour la 
production de nanoparticules d'or dans un environnement aqueux biologiquement 
compatible. Au cours de ce travail de maîtrise, cette méthode a été investiguée en vue 
d'une application pour la fabrication de nanocristaux de médicament en utilisant le 
paclitaxel comme modèle. Deux procédés distincts de cette technologie à savoir 
l'ablation et la fragmentation ont été étudiés. L'influence de la puissance du laser, de 
point de focalisation, et de la durée du traitement sur la distribution de taille des 
particules obtenues ainsi que leur intégrité chimique a été évaluée. Les paramètres ont 
ainsi été optimisés pour la fabrication des nanoparticules. L’évaluation 
morphologique et chimique a été réalisée par microscopie électronique et 
spectroscopie infrarouge respectivement. L'état cristallin des nanoparticules de 
paclitaxel a été caractérisé par calorimétrie differentielle et diffraction des rayons X.  
L'optimisation du procédé de production de nanoparticules par laser fs a permis 
d'obtenir des nanocristaux de taille moyenne (400 nm, polydispersité ≤ 0,3). 
Cependant une dégradation non négligeable a été observée. La cristallinité du 
médicament a été maintenue durant la procédure de réduction de taille, mais le 
paclitaxel anhydre a été transformé en une forme hydratée.                                                               
Les résultats de cette étude suggèrent que le laser fs peut générer des nanocristaux de 
principe actif. Cependant cette technique peut se révéler problématique pour des 
médicaments sensibles à la dégradation. Grâce à sa facilité d'utilisation et la 
possibilité de travailler avec des quantités restreintes de produit, le laser fs pourrait 
représenter une alternative valable pour la production de nanoparticules de 
médicaments peu solubles lors des phases initiales de développement préclinique. 
 
Mots-clés: paclitaxel, nanocristaux, laser femtoseconde, ablation, fragmentation
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         Abstract 
Femtosecond (fs) laser ablation and fragmentation, a novel technique based upon the 
breakdown of material using laser energy was previously used for the production of 
fine gold nanoparticles in suspension. This technique has been newly investigated for 
the fabrication of paclitaxel nanocrystals in aqueous solution.  In this work, we report 
the fabrication and characterization of paclitaxel nanocrystals generated by fs laser 
technology. Two distinct methods of this technology have been explored: ablation 
and fragmentation. The influence of the laser power, focusing position and treatment 
time on the particle size, size distribution and chemical integrity of the drug has been 
studied. Morphology and chemical composition of the finest paclitaxel nanocrystal 
formulation was studied by scanning electron microscopy and Fourier-transform 
infrared spectroscopy respectively. Differential scanning calorimetry and X-ray 
diffraction analyses were employed to evaluate the polymorphic state of the paclitaxel 
nanocrystals. 
Optimal laser fabrication parameters have been established for the fabrication of 
uniformly small sized paclitaxel nanocrystals. Those optimal conditions generated 
finely-sized paclitaxel nanoparticles (400 nm, PDI ≤ 0.3) with a considerable 
degradation. The drug remained crystalline upon nanonization at high power, though 
the anhydrous crystals were converted to a partially hydrated form.  
These findings suggest that drug nanocrystals could be produced using the fs laser 
technology; however, this technique may be inappropriate for drugs sensitive to 
degradation. Moreover, the simple fabrication of drug nanocrystals using the fs laser 
fragmentation presents a great asset for the intial phases of preclinical development of 
many poorly soluble drug candidates, which are not as sensitive as paclitaxel. 
 
Keywords: paclitaxel, nanocrystals, femtosecond, ablation, fragmentation 
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1.1  Introduction 
Pharmaceutical products may be administered through various routes, such as oral, 
nasal, dermal, intravenous, pulmonary, ocular, rectal, or vaginal delivery.  However 
the oral route of administration is preferred, for its many advantages. When ingested 
orally, the drug is absorbed by the gastrointestinal (GI) tract and enters the hepatic 
system. Upon its passage through the GI tract, the drug encounters diverse 
environments with respect to pH, enzymes, electrolytes, fluidity, surface features, all 
of which may influence its absorption (Kwan 1997). Part of the orally administered 
dose may not be available for absorption as a consequence of chemical degradation in 
the GI tract, or it may be metabolized through the gut wall (Figure 1.1). Next, as the 
drug passes through the portal vein, it is carried to the liver before reaching systemic 
circulation, where it is distributed through the bloodstream to various tissues. The 
main problem here is that the liver metabolizes many drugs, and sometimes only a 
small fraction of active drug substance is available for distribution to the rest of the 
body. This phenomenon is known as the first pass effect, and greatly reduces 
bioavailability of some drugs. This effect is defined as the amount of ingested dose 
that reaches the systemic circulation (Mahota 2007).  If administered intravenously 
the drug bypasses absorption and metabolism processes and is directly available in 
the bloodstream, and by definition bioavailability of a drug is 100%. The low oral 
bioavailability of drugs may be attributed to several factors, such as slow dissolution 
rate, poor solubility, metabolism by GI tract or liver due to first pass effect, chemical 
instability in the GI tract and/or poor permeability across intestinal membrane (Horter 
2001).  In addition, the absortption of the drug across the GI tract can highly depend 
upon membrane transport proteins (Rajendran 2010). Also known as drug 
transporters, these proteins allow for the active transport of many drug compounds 
across biological membranes (Lee 2009).  
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Figure 1.1: Drug administration and transport in the body. 
(nihseniorhealth.gov/images/drug_admin1.jpg) 
Pharmacological activity of a drug partly depends on its bioavailability, which 
subsequently depends on its solubility, dissolution rate permeability. Therefore a drug 
must have an adequate aqueous solubility for systemic absorption and therapeutic 
response.  Solubility, a thermodynamic property, refers to the concentration of 
saturated drug in solution, whereas dissolution, a kinetic parameter, is the rate at 
which the drug dissolves (Yvonne 2010). The aqueous solubility of a drug is a prime 
determinant of its dissolution rate. As a result of its poor solubility, the dissolution of 
the drug is so slow that dissolution takes longer than the transit time past its 
absorptive sites, resulting in incomplete bioavailability when administered orally 
(Horter 2001).  In the case of parenteral administration (when the drug is dissolved in 
an organic solvent or micelles), it bears the high risk of precipitation in the circulatory 
system thereby becoming lodged in capillaries and obstructing their blood flow. 
Permeability, solubility and dissolution are major determinants of GI drug absorption. 
Permeability is defined as the rate at which the drug molecule is transported across a 
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membrane (Urban 2007).  It is an important factor controlling the absorption and thus 
the pharmacological activity of a drug (Yvonne 2010). The Biopharmaceutics 
Classification System (BCS) categorizes drugs based upon their solubility and 
permeability (Figure 1.2). The solubility classification is based upon the dose strength 
of the drug. A highly soluble drug has a high strength such that it is soluble in a 
volume of 250 ml or less of aqueous media over pH range 1-7.5. If the drug does not 
exhibit high dose strength, it is considered as poorly soluble (Yu 2002).  The 
pearmeability classification of BCS is based upon the extent of intestinal absorption 
of a drug in humans. Class I consists of drugs that demonstrate both high 
permeability and solubility. Such drugs are appropriate for the development of 
immediate release dosage forms. Class II drugs exhibit low solubility and high 
permeability, and may have limited bioavailability. However by formulating such 
drugs through physical means (eg. micronization or use of cosolvents), their 
dissolution may be improved. Class III (low permeability and high solubility) and 
class IV drugs (low solubility and low permeability) are much more difficult to 
formulate (Yvonne 2010). By altering the chemical structure, the permeability and 
thus the bioavailability of such drugs may be improved. 
 
Figure 1.2: The Biopharmaceutics Classification System (BCS) (Davis 2004) 
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Over the years, progress in combinatorial chemistry, biology and genetics has lead to 
the steady increase in the number of drug candidates under development (Kesisoglou 
2007).  Drug design has attempted to explore new chemical species resulting in more 
complex molecules with higher hydrophobicities. This trend has often resulted in 
worsened aqueous solubility and intestinal permeability. Presently almost 40% of 
drugs in development pipelines and 60% of the drugs directly from synthesis are 
poorly water soluble (Lipinski 2002; Keck 2006). Such drugs typically display low 
bioavailability due to slow dissolution rate (Teeranachaideekul 2008).  
Classic problems associated with poorly soluble drugs are low bioavailability and 
erratic absorption (Muller 2001). Innovative formulation approaches are continuously 
being investigated to increase bioavailability after oral administration or make 
available intravenously injectable forms (Keck 2006). Processes to improve 
solubility, dissolution and subsequent bioavailability of drugs include : (1) 
modification at the molecular level (eg. salt formation, prodrugs, co-solvents, 
complexation), (2) application of colloidal drug delivery systems (eg. micelles, 
emulsions, liposomes)  and (3) modification of the drug properties at the particulate 
level (eg. nanosizing) (Yvonne 2010). These strategies are further discussed in detail 
in this chapter.  
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1.2 Salt formation 
Salt formation is a very common and effective strategy for increasing the solubility, 
dissolution rate and ultimately the bioavailability of poorly soluble ionizable drugs. 
Salts of acidic and basic drugs generally have higher water solubility than their 
corresponding acid or base (Serajuddin 2007).  The salt formation takes place by 
varying the pH and using a counterion, with a significantly different pKa value than 
that of the drug (Yvonne 2010).  The sufficient difference in pKa allows for the pH of 
the solution to be altered and thus generate a salt form of the acidic or basic drug of 
interest.  Potential drug compounds are becoming more and more insoluble and 
sometimes salt formation is not enough to increase their solubility (Serajuddin 2007). 
For instance, for a compound with solubility 1 μg/mL, even a 1000 fold increase in 
solubility by salt formation will give a concentration of only 1 mg/mL, which may 
not be adequate for the purpose of dosage form development. Under such 
circumstances, salt formation may be combined with other solubilization technique to 
obtain an optimal aqueous drug solubility. Furthermore, salt formation is only 
applicable to weakly acidic or basic drugs and not for neutral ones.  In many cases, 
this technique does not achieve better bioavailability because under physiological 
conditions, the salt converts back into the acidic or basic form of the drug.  This latter 
approach only works for weak acids and bases that ionize between pH 2 and pH 9 and 
that are chemically resistant to degradation and hydrolysis.  Furthermore, an extreme 
pH can have biocompatibility issues such as tissue irritation (Narazaki 2007). 
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1.3 Complexation  
Complexation, another approach to dissolve hydrophobic drugs has gained popularity 
in recent years.  Inclusion complexes obtained with cyclodextrins (CDs) are able to 
solubilise certain poorly soluble drugs. CDs are cyclic oligosaccharides derived from 
starch, composed of 6-8 glucopyranose units joined through α-(1,4) glucosidic bonds 
(Figure 1.3) (Brewster 2007).   
 
Figure 1.3 : Chemical structure of a cyclodextrin molecule (Brewster 2007) 
The interior of the complex is relatively lipophilic whilst the exterior is hydrophilic, 
thus making it ideal for the inclusion of poorly water soluble drugs by non covalent 
interaction (Figure 1.4). There exist three natural CDs, α-, β-, and γ-CDs (with 6, 7, 8 
units respectively), and they all differ in ring size and solubilisation properites.  The 
use of CDs is often preferred for solubilisation of drugs (Stella 1997).  For instance 
cosolvents such as alcohols and glycols will increase solubility of the poorly soluble 
drug in a non-linear way, with respect to the co-solvent concentration.  For instance, a 
drug with solubility 0.1 mg/mL in water and 10 mg/mL in propylene glycol does not 
translate into 5 mg/mL solubility in a 50% mixture of water and propylene glycol. On 
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the other hand, CDs solubilize drugs as a linear function of their concentration, such 
that most drugs have a 1:1 complex with CD (Stella 1997). Hence the molecular 
weight of cyclodextrins becomes a limiting factor such that great amounts of 
cyclodextrin may be required for dissolve a small amount of drug. 
  
Figure 1.4: Complexation of drug and cyclodextrin (Stella VJ 1997) 
Presently, there are over 35 different drugs marketed as solid or solution based CD 
complex formulations (Thorsteinn 2004). Both synthetic and natural CDs have been 
employed to enhance drug solubility and are adminsitered via various routes (Table 
1.1). In addition to enhancing solubility and dissolution rate of poorly water soluble 
drugs, CD complexes can reduce or prevent gastrointestinal and ocular irritation, 
prevent drug-drug or drug-additive interactions and convert oils and liquid drugs into 
microcrystalline or amorphous powders (Challa 2005).  
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Table 1.1 : Approved and marketed drug–cyclodextrin complexes in various world 
markets (Davis 2004) 
Drug Administration route Trade name Market 
-Cyclodextrin 
Alprostadil (PGE1) Intravenous Prostavastin, Caverject, 
Edex 
Europe, Japan, 
United States 
Cefotiam hexetil HCl Oral Pansporin T Japan 
Limaprost Oral Opalmon, Prorenal 
-Cyclodextrin 
Benexate Oral Ulgut, Lonmiel Japan 
Dexamethasone Dermal Glymesason Japan 
Iodine Topical Mena-Gargle Japan 
Nicotine Sublingual Nicorette Europe 
Nimesulide Oral Nimedex, Mesulid Europe 
Nitroglycerin Sublingual Nitropen Japan 
Omeprazole Oral Omebeta Europe 
Dinoprostone (PGE2) Sublingual Prostarmon E Japan 
Piroxicam Oral Brexin Europe 
Tiaprofenic acid Oral Surgamyl Europe 
2-Hydroxypropyl- -cyclodextrin 
Cisapride Rectal Propulsid Europe 
Hydrocortisone Buccal Dexocort Europe 
Indomethacin Eye drops Indocid Europe 
Itraconazole Oral, intravenous Sporanox Europe, United 
States 
Mitomycin Intravenous Mitozytrex United States 
Randomly methylated -cyclodextrin 
17 -Oestradiol Nasal spray Aerodiol Europe 
Chloramphenicol Eye drops Clorocil Europe 
Sulphobutylether -cyclodextrin 
Voriconazole Intravenous Vfend Europe, United 
States 
Ziprasidone maleate Intramuscular Geodon, Zeldox Europe, United 
States 
2-Hydroxypropyl- -cyclodextrin 
Diclofenac sodium Eye drops Voltaren Europe 
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1.4 Prodrugs  
A common strategy to increase solubility of a drug is to redesign the molecule to a 
bioreversible, more water soluble derivative, called a prodrug.  A prodrug is a 
pharmaceutical inactive compound that results from transient chemical modifications 
of a biologically active species and is designed to convert to biologically active 
species in vivo by a predictable mechanism (Xiaolong 2006). The drug is 
therapeutically inactive when administered, but becomes activated in the body when 
enzymatic or chemical processes break the promoiety linked to the drug (Figure 1.5) 
(Stella 2007). 
 
 
Figure 1.5: An illustration of the prodrug concept (Stella 2007). 
The successful design of the prodrug is based upon the efficient transformation of the 
promoiety into the active drug in vivo.  There are a variety of chemical structures, but 
most prodrugs are classified based upon their chemical linkage (eg. ester, amides and 
salts) (Fleisher 1996). Other prodrug approaches include conversion of promoieties 
into amines, imides, hydroxyls, thiols carboxyls and carbonyls. A variety of 
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paclitaxel prodrugs have been synthesized in which the promoiety is attached at 
position C2 or C7 (Figure 1.6) (Skwarczynski 2006). 
 
 
Figure 1.6 Paclitaxel prodrug strategies (Skwarczynski 2006). 
Macromolecular prodrugs such as polymer-drug conjugates (polymeric prodrugs) are 
promising to enhance solubility of poorly water-soluble drugs (Duncan 2001). For 
instance, poly (ethylene glycol) (PEG), a water-soluble biocompatible polymer, 
dissolves in organic solvents quite readily. Its high solubility makes it a versatile 
candidate for polymer-drug conjugation (Peng 2008). Silybin, an antihepatotoxic 
agent used to treat liver and gall bladder has a solubility of 0.4 mg/mL. A soluble 
silybin prodrug conjugate with a linear PEG conjugated to the drug via a succinic 
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ester linkage enhanced the solubility to 800 mg/mL. Paclitaxel polymer prodrugs 
have also been reported. The first PEG prodrug of paclitaxel was reported by 
Greenwald et al. (Greenwald 1996).  A water-soluble taxol 2’-PEG ester prodrug was 
designed and showed high solubility (660 mg/mL) (Skwarczynski 2006). 
Prodrugs are not only used to enhance solubility of a drug, but offer other advantages 
as they increase drug stability, achieve sustained drug release, mask the taste of a 
drug and enable site specific drug delivery (Yvonne 2010). However, the use of the 
prodrug strategy is questionable due to the large costs and additional time needed to 
solve formulation and delivery problems (Stella 2007).  
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1.5 Cosolvents 
The solubility of a drug may be enhanced by dissolving it in a cosolvent mixture, 
composed of water and a solvent (eg. ethanol, propylene glycol, glycerol and/or PEG) 
(Yvonne 2010).  To achieve relatively high drug solubility, the concentration of the 
cosolvent mixture is usually high as well.  Hence, upon dilution of the cosolvent 
mixture in the intravenous fluids or blood, the drug may easily precipitate (Singla 
2002).  
The use of cosolvent presents certain disadvantages such that an excess of solvent 
may be unsuitable and toxic for parenteral formulations. The intrinsic toxicity of 
cosolvent vehicles can be reduced by using a mixture of cosolvents or combining 
them with surfactants.  Only few surfactants and organic cosolvents are regarded as 
safe for human use. Even fewer are compatible with injectable formulations possibly 
causing precipitation, pain, inflammation, and hemolysis. However, by raising the 
number of excipients in a given formulation, the risk of incompatibilities increases 
(Li 2007). Nonetheless, cosolvent strategies are explored to enhance solubility of 
many poorly water-soluble pharmaceutical agents. For instance, a cosolvent mixture 
of ethanol, polysorbate (Tween 80) and surfactant (Pluronic L64) in a 3:1:6 (v/v/v) 
ratio was used to formulate the poorly water-soluble drug paclitaxel (0.3 μg/mL).  
The drug concentration in the cosolvent formulation was reported at 5 mg/mL, but the 
formulation became unstable upon dilution with water (Singla 2002). 
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1.6 Surfactants and Micelles  
Surfactants are amphiphilic agents with a hydrophilic head and hydrophobic tail.  
This specific nature of surfactants gives them unique activity at interfaces, wherein 
they significantly reduce the surface tension of water.  At low concentrations, these 
molecules are freely dispersed in an aqueous environment, however as the 
concentration is increased, the free energy of the system augments as a result of 
unfavourable interactions between the hydrophobic regions and the surrounding water 
molecules (Gaucher, in press).  At a precise concentration, the surfactant molecules 
arrange themselves to form aggregates called micelles, thereby minimizing the energy 
of the system (Figure 1.7) (Torchilin 2007).  The minimum surfactant concentration 
at which micelles assemble is referred to as the critical micellization concentration 
(CMC).  Micelles are in dynamic equilibrium with free molecules in solution, and so 
they are constantly dissociating and reforming (Torchilin 2007).  The size of micelles 
varies and depends on the size, shape and number of surfactant monomers used.  The 
formation of micelles is driven by the decrease of free energy in the system because 
of the removal of hydrophobic fragments from the aqueous environment and the re-
establishing of the hydrogen bond network in water.  Consequently, hydrophobic 
fragments of the amphiphilic molecules form the core and hydrophilic fragments 
form the shell (Torchilin 2007).  Due to such a structure, micelles solubilise 
molecules of poorly soluble nonpolar drugs within its core and polar drug molecules 
may be adsorbed on the micelle surface (Jones 1999).  Such solubilisation using 
micelle-forming surfactants results in an increased water solubility of poorly soluble 
drug and its improved bioavailability, and enhanced permeability across biological 
barriers (Torchilin 2001; Torchilin 2007).  
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Figure 1.7: Representation of micelle formation at CMC (Wikipedia) 
Polymeric micelles have attracted much attention over the years. Polymeric micelles 
are formed by block co-polymers consisting of hydrophilic and hydrophobic 
monomer units with the length of a hydrophilic block exceeding to some extent that 
of a hydrophobic one (Gaucher 2005).  Similar to micelles formed by the 
conventional surfactants, block copolymer micelles assume a core-shell structure 
where the core is comprised of hydrophobic blocks, and is stabilized by the corona 
composed of hydrophilic chains (Gaucher, in press).  In comparison to the 
conventional micelles, polymeric micelles form at lower CMC and are more stable 
upon dilution accordingly protecting the incorporated drug from fast degradation 
(Devalapally 2007). Genexol – PM is a methoxy-PEG-poly (D-L-lactide) micelle 
formulation of paclitaxel that obtained a pre-market approval in Korea in 2006.  In 
vivo studies demonstrated that the antitumor efficacy of this formulation is better than 
the current market formulation of paclitaxel, Taxol® (Yvonne 2010).  
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1.7   Emulsions, microemulsions and self-     
    emulsifying delivery systems 
An emulsion is composed of a minimum of two immiscible liquid phases (eg. oil and 
water), where a dispersed phase (dispersed globules) is in a continuous phase (liquid 
phase) and the whole system is stabilized by an emulsifying agent (Mahato 2007). 
Depending on which phase is dispersed into the other, either an oil-in-water (o/w) or 
water-in-oil (w/o) emulsion is obtained.  Micron or submicron sized droplets are 
formed upon applying high energy to the system (Yvonne 2010).  Microemulsions; 
much smaller one-phase systems are more stable colloidal solutions.  Microemulsions 
contain appropriate mixture of oil (polar lipids) water and surfactants, and the oil 
component is used to deliver the poorly soluble drug.  In addition, whereas emulsions 
are composed of spherical droplets, microemulsions range from droplet-like 
micellular structures to bicontinous structures. Self-emulsifying drug delivery 
systems (SEDDS), composed of an isotropic mixture of drug, lipid and surfactants, 
are used to deliver hydrophobic drugs.  SEDDS form fine emulsion droplets (50-100 
nm) upon dilution in physiological fluids (Tang 2008). Thus, the hydrophobic drug 
remains in solution and is delivered to the gut.  SEDDS exist as solutions or are made 
into solid dosage forms. A few of the marketed o/w emulsion products include 
Diazepam®, Etomidate® and Propofol® (Muller 2005).  
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1.8 Liposomes 
Liposomes are spherical vesicles composed of phospholipids self-assembled in 
aqueous medium (Rawat 2006).  Due to their amphiphilic nature, lipids in excess of 
water spontaneously self-associate above a concentration called the critical 
aggregation concentration, which is in the order of 10-10 M.  The self-assembly 
process is spontaneous and cooperative (Mahato 2007). The lipid moieties 
spontaneously orient in water, and the lipid chains orient inward, giving rise to 
bilayer structures (Figure 1.8).  The aggregation phenomenon is a result of both the 
polar interactions between the hydrophilic heads of the phospholipids, and the 
hydrophobic effect of the aliphatic chains (Simard 2007). 
 
Figure 1.8: Structure of a liposome (Devalapally 2007) 
Liposomes range from 50 nm to a few micrometers in diameter (Haley 2008). They 
consist of one or more concentric lipid bilayers separated by water compartments.  
The rationale of using liposomes as drug delivery systems to the cells was originally 
based upon the possibility of fusion of the liposome to the target cell membrane. 
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Hence, the preparation of liposomes had to be prepared from natural lipids found in 
cell membrane, such as glycerolipids, sphingolipids and sterols (Simard 2007). 
Synthetic lipids that mimic the structure and physicochemical properties of natural 
lipids may also be used to fabricate liposomes. Furthermore, these liposomes offer 
greater advantage such that they may be altered for improved properties. In 
comparison to other colloidal drug delivery systems, liposomes have the ability to 
encapsulate both hydrophilic (inside the aqueous region) and lipophilic drugs within 
the bilayer regions.  
Liposomes are classified and described according to their size, the number of 
bilayers, or their preparation method. Multilamellar vesicles (MLV) are usually 1-5 
μm in diameter, whereas unilamellar vesicles (UV) range from 40 nm to 1 μm. There 
exist four major types of liposomes: conventional, sterically stabilized, targeted and 
cationic (Simard 2007).  Conventional liposomes are either neutral or negatively 
charged, and are composed of phospholipids, glycolipids, and/or cholesterol. Such 
liposomes have a limited circulation lifetime because they are removed by cells from 
the mononuclear phagocyte system (MPS) (Appendix I) (Janoff 1999). These 
liposomes are mainly used for passive targeting to the phagocytic cells of the MPS, 
localizing predominantly in the liver and spleen.  
Sterically stabilized liposomes have a polymer coating to obtain prolonged circulation 
times.  PEGylated (polyethylene glycol) lipids reduce the uptake of the liposomes by 
the MPS and subsequently circulation time of the vesicle is greatly increased.  By 
residing in the bloodstream for a longer time, PEGylated liposomes (also known as 
STEALTH® liposomes) could localize into tumours and most inflammation sites 
(Mahato 2007).  Targeted liposomes usually have a biological moiety attached to 
enable recognition by a specific receptor at the site of interest.  Targeting ligands 
include monoclonal antibodies (generating an immunoliposome), vitamins or specific 
antigens.  Most of the targeting liposomes are also PEGylated, and so are able to 
target nearly any cell type in the body and deliver drugs.  Finally, cationic liposomes 
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are positively charged and are mainly used for the delivery of nucleic acids 
(Papahadjopoulos 1991). The positively charged liposomes interact with the 
negatively charged backbone of DNA or RNA, and lead to neutralization. 
 
Figure 1.9:  Classification of liposomes 
(www.imcr.uzh.ch/static/onkwww/images/lipos4.gif) 
Liposomes were one of the first drug delivery system to be approved for clinical use, 
and today there exists many liposomal formulations. One very popular formulation is 
Doxil®, which encapsulates the poorly soluble drug Doxorubicin in 80-100 nm-sized 
liposomes of PEGylated distearoyl phosphatidyl ethanolamine, hydrogenated soy 
phophatidylcholine and cholesterol (Yvonne 2010).  
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1.9 Polymer Solid dispersions  
As discussed earlier, polymers play a vital role in solubilising poorly soluble drugs. 
Alternative applications of polymers include their use in solid dispersions as a 
strategy to improve solubility of poorly soluble drugs (Leuner 2000).  
Solid dispersions consist of molecularly or physically dispersing drug in a water-
soluble carrier (eg. PEG or PVP) or a water insoluble carrier (Sivert 2009). Drug 
dissolution can be improved by molecularly dispersing a drug in a hydrophilic 
polymer matrix via preparation processes such as solvent evaporation or hot-melt 
extrusion. Polymers have been used quite extensively to generate solid dispersions, 
because they make amorphous solid dispersions. Solubility of a given solid is a sum 
of crystal packing energy, cavitation and solvation energy. Different solid-state forms 
of a material have different crystal packing energy. The amorphous form, due to 
absence of an ordered crystal lattice requires minimal energy provides the maximal 
dissolution advantage as compared to the crystalline and hydrated forms of a drug 
(Vasconcelos 2007). Polymers used include both synthetic (PEG, polymethacrylates), 
and natural polymers such as hydroxymethylcellulose (HPMC), ethylcellulose and 
CDs (Vasconcelos 2007).  When the solid dispersion is exposed to an aqueous milieu, 
the carrier dissolves allowing the release of the incorporated drug.  
Due to the intensive work involved in the optimization of solid dispersions, the latter 
are rarely considered as a viable option to formulating poorly-water soluble drugs. In 
addition, the amorphous form of the drug within the solid dispersion may undergo 
crystallization over time.  
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1.10 Size reduction  
A much more classical method to increase drug dissolution rate is through size 
reduction (Keck 2006). The Noyes-Whitney equation (equation 1), where dW/dt is  
Equation 1                 
the rate of dissolution, A is the surface area of the solid, C is the concentration of the 
solid in the bulk dissolution medium, Cs is the concentration of the solid in the 
diffusion layer surrounding the solid, D is the diffusion coefficient, and L is the 
diffusion layer thickness explains that dissolution rate may be readily improved by 
reducing the size of the drug particle, and thereby increasing surface area available 
for dissolution (Figure 1.10) (Merisko-Liversidge 2003; Muller 2004). The size 
reduction also decreases the thickness of the diffusion layer around each particle, thus 
further promoting the dissolution. The surface area may be adjusted by altering the 
particle size (eg. micronization). Micronization, which involves coarse drug powder 
milled into an ultrafine powder of particle size distributions in the range of 1 - 25 μm, 
is a common method used to improve bioavailability of the poorly soluble drug 
(Merisko-Liversidge 2003). 
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Fig. 1.10. Dissolution velocity dc/dt (or dW/dt) and saturation solubility Cs as a 
function of the size of drug powders ranging from coarse to nanonized drugs (Muller 
2004) 
Many of the new drugs exhibit such a low solubility that micronization is insufficient 
to increase the surface area of the drug to a large extent. At very low solubility, the 
achieved increase in dissolution rate is not significant enough to lead to high enough 
bioavailability. Though micronization increases dissolution rate, it does not change 
the saturation solubility of the poorly soluble drug and consequently desired 
therapeutic blood levels are not attained. Hence, the next approach involves further 
reduction of the drug particles, down to the nanoscale.  Moreover, according to the 
Ostwald-Freundlich equation (equation 2),  
Equation 2                
 
where R is the gas constant, T is the absolute temperature, M the molecular weight of 
the solid in solution, σ is the interfacial tension between the solid and liquid, ρ is the 
density of the solid, and S1 and S2 are the solubilities of particle of radius r1 and r2, 
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respectively, the equilibrium solubility of particles increases with decreasing particle 
size.  Particularly size reduction in the range below ca. 1 µm is accompanied by an 
increase in saturation solubility (Borm 2006).  
Though many textbooks and articles follow this theory, the validity of the Oswald-
Freundlich equation to describe the relationship between the size of a particle and its 
solubility is controversial (Godec 2009, Nancollas 2009).  Experimental observations 
have shown that Oswald ripening is not due to the increased solubility of smaller 
crystals but rather to a negative tension between a solid and a solution (Wu 1998).  
Oswald stated that the driving force for ripening is the variation in solubility between 
large and small particles. However, the alternative mechanism concludes that the 
ripening is due to a thermodynamically unstable interface between the solid and 
solution. Wollaston and Curie assumed the hypothesis that finely divided solids 
should have larger solubilities than coarser ones in the late 19th century. Later Oswald 
and Freundlich used similar arguments to establish the equation above and prove that 
solubility of finely sized crystals in a function of particle size. However, when the 
first experimental investigations were made to test the supersaturation, particle size 
and solid-liquid interfacial tensions, limitations were encountered and the Oswald-
Freundlich equation was subjected to criticism (Wu 1998). Despite the controversy, 
many believe that particle size reduction does indeed lead to enhanced dissolution 
rate. 
Nanosizing is the reduction of the active pharmaceutical ingredient (API) particle size 
down to the sub-micrometer range (Kesisoglou 2007). By definition, drug 
nanocrystals are nanoparticles of pure crystalline drug without any matrix material 
typically ranging from 200 – 500 nm in size (Muller 2001).  The following chapter 
comprehensively describes the advantages, methods of fabrication and applications of 
drug nanocrystals.   
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2.1 Introduction 
 
Whilst reduction in particle size has been applied in the pharmaceutical field for 
several decades, newer technologies and the deeper understanding of colloidal drug 
systems has allowed for the production of nanoscale drug particles.  Drug 
nanocrystals are composed of pure crystalline drug devoid of polymeric or lipidic 
carriers and may be sized from few nanometers up to 400 nm. Nanosuspensions are 
dispersions of the nanocrystals in a liquid media, which are stabilized by surfactants 
or polymeric stabilizers (Junghanns 2008). Nanosuspensions overcome the delivery 
issues of poorly soluble compounds by obviating the use of potentially harsh 
vehicles, such as pH-buffers or cosolvents, thereby reducing toxicity and increasing 
efficacy (Rabinow 2004). 
As presented section 1.10, a significant feature of drug nanocrystals is the increase in 
dissolution velocity (subsequently in bioavailability). Another exceptional feature of 
nanosuspensions is the increased adhesiveness compared to microparticles which is 
an additional factor for improving the oral absorption of poorly soluble drugs 
(Junghanns 2008).  As a result of this phenomenon, nanocrystals remain in contact 
with the gut wall for longer time, thereby enhancing bioavailability of the drug upon 
oral administration (Gao 2008).  
Being physically stable and displaying increased dissolution rate, a nanocrystal 
formulation greatly enhances biological performance of poorly soluble drugs 
(Merisko-Liversidge 2003).  
By increasing the dissolution rate, nanonization enhances the rate and extent of 
absorption of drugs administered orally so that the bioavailability is less affected in 
the fed/fasted state.  For instance, by nanosizing the active ingredient (MK-0869) of 
the drug EMEND®, previously FDA approved for prevention of chemotherapy-
induced nausea, the advantages of a nanocrystalline formulation over a conventional 
dosage form were confirmed (Figure 2.1) (Wu 2004). Additionally, owing to their 
small size, stable drug nanocrystals may be injected by the intravenous (i.v.) route 
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without the risk of embolic complications. More importantly, the total drug amount in 
the formulation may be adjusted to high levels, allowing usage of smaller 
administration volumes.   
In this chapter, various methods of nanocrystal production, their characterization and 
applications are discussed in detail. 
 
 
 
 
Figure 2.1: Comparison of mean (±S.E.) plasma concentrations of MK-0869 (active 
ingredient of EMEND®) following oral administration in Beagle dogs (N = 5) of a 
conventional suspension (●, fasted; ○, fed) and a NanoCrystal® dispersion 
formulation ( , fasted; , fed) of MK-0869 at a dose of 2 mg/kg (Wu 2004). 
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2.2 Methods of nanocrystal fabrication 
   
Methodologies for the generation of drug nanocrystals are mainly categorized as 
“bottom-up” or “top-down” methods (Van Eerdenbrugh 2008).  The first is based 
upon the strategy of growing drug nanocrystals, whereas the latter breaks down 
coarse drug powder into nanoparticles.  
 
2.2.1 Bottom-up strategies 
 
Precipitation techniques and supercritical fluid technology are the commonly used 
bottom-up approaches to fabricate drug nanocrystals.   
The precipitation technique consists of dissolving the poorly soluble drug in a solvent 
(usually organic) and adding this solution to an anti-solvent (eg. water) under 
agitation (Kesisoglou 2007).  This leads to a supersaturation which results in rapid 
nucleation of the drug, thereby forming nanoparticles (Gao 2008).  Several 
parameters such as stirring rate, volume ratio of anti-solvent/ solvent and drug content 
require optimization for the production of uniformly sized nanoparticles. A faster 
stirring rate generates smaller particles and a greater anti-solvent/solvent ratio brings 
about a faster nucleation. The drug content should be adjusted to a moderate level, 
because very large drug quantities may cause uncontrolled agglomeration of the 
nanocrystals. The drug nanocrystals are further processed for removal of organic 
solvent.  
The principle advantage of the precipitation technique is that it is relatively simple 
and inexpensive, however this technique does have its disadvantages. It is known that 
the particle size is not always controlled using this method because growth of the 
crystals is not hindered, and microcrystals are very often generated (Keck 2006). In 
order to avoid spontaneous agglomeration and subsequent formation of microcrystals, 
stabilizers are used. Another limitation of this technique is that the drug must be 
soluble in a solvent which is miscible with the anti-solvent. This poses difficulties 
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because most poorly soluble drugs needing to be nanosized, are poorly soluble in 
both aqueous and organic solvent, thus making them unsuitable candidates for the 
precipitation technique (Grau 2000). Amorphous drug content often is generated 
during the precipitation process. Though this state of a drug is more soluble and 
exhibits a higher dissolution than the crystalline state, it is not as stable and converts 
to crystalline over time (Gao 2008).  Despite its limitations, liquid precipitation is low 
cost method offering convenient processing of nanocrystals (Zhang 2009). This 
bottom-up technology is marketed by DowPharma (Midland, MI, USA) and by 
BASF Pharma Solutions (Florham Park, NJ, USA) (Kesisoglou 2007).  
 
Supercritical fluid based technologies, such as rapid expansion from supercritical 
solutions (RESS), rapid expansion from supercritical aqueous solutions (RESAS), 
and supercritical anti-solvent methods (SAS), have been investigated as an alternative 
bottom-up strategy for the fabrication of drug nanocrystals (Date 2004). This 
approach requires complex operating conditions and induces high costs (Zhang 
2009). 
The RESS method consists of dissolving the drug in a supercritical fluid (eg. CO2) at 
a programmed temperature and pressure. The drug solution is introduced into a 
precipitation unit and allowed to expand rapidly though a capillary into a region of 
lower pressure and temperature (Date 2004). This phenomenon results in the 
dissolved drug precipitating rapidly as a finely sized powder, thus generating 
nanocrystals. The shortcoming of this method is that only drugs exhibiting solubility 
in supercritical fluids could be used. Similar to the liquid precipitation technique, 
generation of microcrystals are also obtained, resulting in large size distribution. The 
RESAS is an evolution of the RESS method, such that an aqueous solution containing 
stabilisers is used in addition to the supercritical fluid. Though size is better 
controlled, this technique displays similar concerns because of the use of solvents. 
The SAS method consists of dissolving the drug in an appropriate organic solvent or 
co-solvent, and then atomizing it into an excess flowing continuum of supercritical 
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CO2, thus forming nanoparticles in a dried state. Hydrophobic drugs with poor 
solubility in supercritical fluids may be processed using the SAS procedure, however 
broad particle size distribution is obtained.  
 
 
2.2.3 Top-down strategies 
 
Top-down methods are more widely employed for the production of drug 
nanocrystals. This specific strategy relies on mechanical attrition to break down large 
crystalline particles into nanoparticles (Kesisoglou 2007). Such technologies include 
high-pressure homogenization and media milling.  
 
Media milling (or wet milling) is based upon an attrition procedure in which 
micrometer sized drug crystals are milled in the presence of grinding media and 
stabilizers (Rabinow 2004). This patent protected technology was developed in 1990 
by Liversidge et al. (Merisko-Liversidge 2008). In this process, a nanocrystal 
suspension is generated by high shear milling equipment composed of a milling 
chamber, milling beads (or grinding media), a rotor and a recirculation chamber 
(Figure 2.2).  
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Figure 2.2:  Schematic representation of the media milling process (Date 2004). 
 
The poorly soluble drug is dispersed in an aqueous surfactant solution, and the 
resulting suspension is wet-milled with the grinding media (Gao 2008).  The grinding 
material spherical in form, is typically composed of zirconium oxide, zirconium 
silicate or other media such as glass, titania, alumina (Hu 2004).  The stabilizers (or 
surface modifiers) used comprise of various polymers, low molecular weight 
oligomers, natural products and surfactants.  During the milling process, the 
generated shear forces and those created during impaction of the milling media with 
the solid drug provide high energy to break the drug crystals into nanoparticles 
(Merisko-Liversidge 2003).  Particle size is determined by stress intensity (which is a 
function of kinetic energy of the grinding beads), number of contact points (which 
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may be increased by using smaller grinding media), and the time of milling (Rabinow 
2004).  The optimization of the following parameter: drug content, amount of 
grinding or milling pearls, milling speed and time are important for the generation of 
desirable nanosuspensions.  Liversidge et al. reported that particles of Naproxen, a 
poorly soluble drug were reduced to 270 nm, from an average initial size of 20-30 μm 
over a period of 5 days of wet milling.  PVP K-15 was used as the stabilizer (5:3 drug 
to stabilizer ratio) and the nanosuspension remained physically and chemically stable 
for up to 4 weeks at 4°C (Hu 2004). 
Though the wet-milling procedure enables the production of stable drug 
nanosuspensions, there are a few drawbacks to this technique. Not only is it time 
consuming, but there have been reports on the contamination of the product by 
grinding material (Muller 2001).  Erosion of the grinding material may contaminate 
the final drug product.  In addition, wet-milling is a batch process; therefore batch-to-
batch variations may be detected in the quality of the dispersion, processing time, 
degree of drug crystallinity and particle size distribution. Such variations affect the 
drug particle size and the efficiency of the delivery system. Moreover milling over 
several days may also bring risks of microbiological problems, particularly when 
performing the process at 30°C or using a dispersion media providing nutrition to 
bacteria (Gao 2008).  Regardless of these limitations, this mechanical method of 
producing nanocrystals is successfully marketed as the NanoCrystal® technology 
(Élan) (Merisko-Liversidge 2008).  Four oral products generated via the 
NanoCrystal® technology are currently marketed in the US and other countries: 
Rapamune®, Emend®, TriCor 145® and MegaceES® (section 2.5).    
 
Another top-down method, known as high pressure homogenization, was invented by 
Muller et al.  in the mid 1990s (Muller 1998).  Homogenization involves the forcing 
of a drug suspension under pressure through a valve with a narrow aperture (Figure 
2.3).  Therefore, the formation of the nanosuspension is based on the cavitation 
energy generated in the high pressure homogeniser (eg. the piston-gap homogenizer).  
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In this process, the poorly soluble drug is dispersed in an aqueous surfactant solution 
via high speed stirring, and the resultant suspension is passed though a high pressure 
homogeniser (gap width of approximately 25 μm) at a pressure of 1500 bar over 3- 20 
homogenization cycles (Hu 2004; Rabinow 2004).  Due to the narrowness of the gap, 
the streaming velocity of the drug suspensions and the dynamic fluid pressure 
increase. Furthermore the static pressure of the fluid decreases below the boiling 
point of water (at room temperature), and as a consequence the water boils and gas 
bubbles form which implode when the fluid leaves the homogenization gap (Muller 
2001).  The generated cavitation forces are very strong and break the drug particles, 
forming nanocrystals of approximately 40 – 500 nm.  The size is dependent upon the 
hardness of the drug substance and may be controlled by adjusting the processing 
pressure and the number of cycles applied (Hu 2004). 
 
Figure 2.3: High pressure homogenization technique: (right) forcing of drug 
suspension through narrow valve, (left) fabrication of drug nanocrystals due to 
generated forces (Junghanns 2008). 
 
This process also is time-consuming as it takes several cycles to reduce particle size 
which highly depends on the pressure in the homogenizer. Moreover, the drug 
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powder requires micronization prior to homogenization in order to avoid blockage of 
the narrow valve.  Changes in drug crystallinity have been reported with this process. 
A portion of drug nanoparticles was reported as amorphous, and in some cases, 
complete transformation to amorphous state was observed (Muller 2001). In 
comparison to the milling procedure, high pressure homogenization displays much 
less contamination due to erosion of the equipment. Muller et al. investigated the 
contamination of nanosuspensions produced under harsh conditions (eg. 20 cycles 
and pressure of 1500 bar), and found iron contamination to be under 1 ppm, low 
enough to not pose health issues (Krause 2000). 
DissoCube® was the first high pressure homogenization technology to be marketed. It 
involved the fabrication of nanocrystals in water.  Shortly after, Nanopure® 
technologies was developed which involved homogenization in non-aqueous media 
or mixtures of water and immiscible substances (eg. PEG).  The company Baxter 
developed a combined technology known as NANOEDGE® system in which 
homogenization procedure is combined with the precipitation technique discussed 
earlier. The homogenization step is used to avoid growth of the drug particles after 
precipitation takes place (Gao 2008). 
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2.3 Characterization of Nanocrystals 
The essential characterization parameters for nanosuspensions include evaluation of 
size and size distribution, zeta potential, crystalline state, dissolution velocity and 
saturation solubility, surface hydrophilicity/hydrophobicity (Patravale 2004).  Other 
tests include chemical investigation such as evaluation of possible degradation 
products and evaluation of moisture of nanocrystals (for lyophilized API) (Rabinow 
2004). 
The mean size and size distribution (polydispersity index) are important parameters 
because they govern properties such as saturation solubility, dissolution velocity, 
physical stability, and certain biological performances. Photon correlation 
spectroscopy (PCS) or dynamic light scattering technique (DLS) are employed, but  
limited to measuring sizes of 3 nm to 3 μm, therefore laser diffractrometry (LD) is 
used to detect aggregates of drug nanocrystals.  LD is able to measure particles of 
0.05 μm to 2000 μm (Muller 2001).  Scanning (or transmission) electron microscopy 
(SEM, TEM) may also be used for size evaluation.  The polydispersity index (PDI) is 
an important index of physical stability of the nanocrystal.  PDI values vary between 
0 (monodisperse particles) to 1 (broad distribution), however lower values (≤0.3) are 
usually more appreciable for long-term stability of the nanosuspension. 
Surface charge is an important parameter also governing the stability of the 
nanosuspensions. It is measured by means of electrophoresis and is expressed as 
electrophoretic mobility or converted to zeta potential.  This measurement allows for 
the prediction of storage stability of the nano-dispersions.  Usually the particles with 
sufficient zeta potential are less likely to aggregate.  Literature states that a zeta 
potential of at least -30 mV for electrostatic and -20 mV for sterically stabilized 
nanoparticles is desirable for physically stable suspensions (Gao 2008).  
Evaluation of crystalline character is required to ensure that crystallinity of the drug 
has been retained upon nanonization because fabrication procedures may alter the 
polymorphic state of the drug. For instance high pressure homogenization may 
generate nanocrystals with amorphous fraction (Muller 2001).  Differential scanning 
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calorimetry (DSC) and X-ray diffraction analysis (XRD) may be used to evaluate the 
polymorphic state. 
Dissolution velocity and saturation solubility need to be evaluated in comparison to 
the traditional dosage forms of the drug. The determination of such parameters also 
helps to anticipate the in vivo performance (eg. blood profiles, plasma peaks and 
bioavailability) of the nanocrystal formulation (nonetheless in vivo experiments 
should be followed). Shaking experiments at various temperatures in an artificial 
medium such as saline, may be used to assess solubility. The dissolution rates are 
determined using specific methods described in the Phamacopoeia (Gao 2008). 
Characterization of surface properties is essential as it provides insight of the in vivo 
performance of the generated nanocrystals.  In the case of intravenous injection, the 
in vivo behaviour of the drug depends on organ distribution, which in turn depends on 
its surface properties such as hydrophibicity and interactions with plasma proteins 
(Patravale 2004).  Hydrophobic interaction chromatography is able to evaluate the 
surface hydrophobicity of nanocrystals.  Two-dimensional gel electrophoresis (2-D) 
PAGE is a method employed for the qualitative and quantitative measurements of 
protein adsorption after intravenous injection of nanosuspension (Gao 2008).  Such 
analysis is imperative to evaluate the in vivo biological performance of the fabricated 
nanocrystals and establish in-vitro/in-vivo correlation.  
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2.4 Administration routes of nanosuspensions  
Nanocrystals generated either by top-down or bottom-up approaches are stabilized 
with surfactants and/or polymer stabilizers in nanosuspensions, which may be 
processed into solid dosage forms.  Thus drug nanocrystals may be administered 
orally as tablets (or capsules), while drug nanosuspensions may be directly given 
carefully through i.v. administration.  In order to transform an aqueous dispersion into 
a dry powder, lyophilisation or spray-drying may be used (Muller 2004).  Spray 
drying involves the use of high temperatures, which may be a problem for 
thermolabile drugs. Alternatively, lyophilisation is used, in which a cryoprotective 
agent (eg. mannitol or sucrose) is added to the nanosuspension to prevent aggregation 
of the nanocrystals in their dried state (Teeranachaideekul 2008).  The application of 
drug nanocrystals is outlined in the next sub-sections.  
 
  2.4.1 Oral route 
The oral route of administration is preferred to deliver numerous drugs, for its many 
advantages. However when administered as a nanosuspension there is an increased 
drug concentration gradient between the gastrointestinal tract and blood vessel, as a 
result of the increased saturation solubility and dissolution velocity. This leads to less 
variabililty in the fed/fasted state. Thus the nanosizing of the drug improves 
absorption to a large extent and leads to an enhanced bioavailability. In addition, due 
to their uniquely small size, nanoparticles exhibit increased adhesiveness to the gut 
wall.  A classic example of this is Danazol, a poorly soluble gonadotropin inhibitor. It 
was shown that an orally administered nanosuspension of this drug, led to an absolute 
bioavailability of 82.3%, in comparison to the marketed formulation (Donacrine®) 
which displays only 5.2% (Liversidge 1995).  
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           2.4.2 Parenteral Administration  
Parenteral administration is an invasive route often related to problems such as 
limited number of acceptable expedients approved for parenteral use, stringent 
requirements of aseptic production procedure, patient non-compliance and biological 
issues such as toxic or allergic reactions (Patravale 2004).  In spite of its limitations 
the parenteral route present advantages such as i.v. administration of a drug results in 
100% bioavailability in the body, so only a small dose of drug is required.  For i.v. 
administration, the drug particles must be less than 5 μm in diameter in order to avoid 
blockage and embolism in the blood capillaries (Gao 2008). Nanosuspensions 
provide an excellent advantage because they only contain very little stabilizers and no 
added solvents, therefore biological risks associated with excipients and co-solvents 
are avoided.  The nanosuspension may be sterilized by gamma irradiation, filtration 
sterilization, thermal sterilization or fabricated asceptically (Na 1999). It is important 
to select the optimal sterilization technique so that the properties of the drug 
nanosuspension do not change.  
 
  2.4.3 Ocular adminstration route 
Suspensions and ointments have been proposed for the ocular delivery of poorly 
soluble drugs. However their solubility is still limited in lachrymal fluids and 
effective drug performance is usually not obtained (Patravale 2004). 
Nanosuspensions of the poorly soluble drugs display a remarkably increased 
solubility, and provided an effective performance of the drug.  Kassem et al. 
fabricated nanosuspensions of three poorly soluble glucocorticoid drugs; 
hydrocortisone, prednisolone and dexamethasone (Kassem 2007).  They investigated 
ocular bioavailability of the nanosuspensions in comparison to conventional eyes 
drops (solution of microsuspensions), and concluded that nanosuspensions were 
effective in ophthalmic drug delivery because fewer side effects were observed.  
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  2.4.4 Pulmonary route 
Presently, drugs exhibiting poor solubility in pulmonary secretions are formulated as 
suspension aerosols or dry powder inhalers containing micron sized drug particles 
(Patravale 2004).  The wide particle size distribution of the microparticulate drug 
causes problems such as: unwanted deposition of the drug particles in the pharynx 
and mouth, clearance of the drug by cilia movement in the lungs, and limited 
diffusion and dissolution of the drug at the site of action.  Nevertheless, these 
problems may be resolved by applying nanosuspensions as pulmonary drug delivery 
systems. The preferred size of inhaled nannoparticles is approximately 1 – 5 μm 
(Yang 2008).  The increased dissolution and subsequent solubility allow for a larger 
drug concentration in the lung, leading to greater drug levels at the absorption site.  
Also since nanocrystals have a natural tendency to adhere to mucosal surfaces at the 
site of absorption, the residence time of the drug increases and it is not easily cleared 
by the cilia movement (Ponchel 1997).  
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2.5 Marketed Nanocrystalline drugs 
Though nanocrystals are applied through various administration routes, most of the 
nanocrystalline API on the market are oral dosages forms. Currently there are several 
marketed pharmaceutical products utilising nanocrystalline drug (Table 2.1). 
NanoCrystal® technology (Elan) is used to fabricate four oral products Rapamune®, 
Emend®, TriCor 145® and MegaceES®  (Merisko-Liversidge 2008).  TriglideTM is 
marketed as SkyPharma IDD-P technology.  
 
Table 2.1: Summary of nanocrystalline products currently on the market (Junghanns  
2008) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Nanonization had allowed these poorly soluble drug compounds to exhibit a faster 
dissolution rate and solubility and thus an enhanced bioavailability.  For instance 
Tricor® marketed by Abbott Laboratories has an active ingredient of fenofibrate; a 
lipophilic compound and almost insoluble in water (Junghanns 2008).  Fenofibrate 
Product Drug 
compound 
Indication Company Nanoparticle 
technology 
RAPAMUNE® Sirolimus Immunosuppressant Wyeth Elan Drug 
Delivery 
Nanocrystals® 
EMEND® Aprepitant Antiemetic Merck Elan Drug 
Delivery 
Nanocrystals® 
TriCor® Fenofibrate Treatment of 
hypercholesterolemia 
Abbott Elan Drug 
Delivery 
Nanocrystals® 
MEGACE® ES Megestrol 
acetate 
Appetite stimulant PAR 
Pharmaceutical 
Elan Drug 
Delivery 
Nanocrystals® 
Triglide™ Fenofibrate Treatment of 
hypercholesterolemia 
First Horizon 
Pharmaceutical 
SkyePharma 
IDD®-P 
technology 
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may not be converted to a salt because it has no ionisable moiety.  Formulation 
approaches involving lipids and surfactants do enhance the absorption of the drug in 
fed patients only.  However by nanosizing the drug, not only is solubility enhanced, 
but the drug is bioequivalent in the fed and faster state.  
As discussed, there are several advantages of nanocrystal technology. Nanonization is 
a simple, elegant and universal technique that may be applied to many poorly soluble 
drugs.  The top-down strategies to fabricate nanocrystals are energy intensive and 
time consuming techniques; however, several drugs have been successfully 
formulated and marketed based upon such methods.  The next chapters describe an 
alternative technique that has been explored for the fabrication of paclitaxel 
nanocrystals in the present study. 
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CHAPTER 3:  
Laser Fabrication of Nanocrystals in Liquid
  
3.1 Introduction 
Pulsed laser ablation (PLA) was introduced in the early 1960s and consists of the 
collective ejection of material from a target following irradiation by short, intense 
bursts of light (Yang 2007; Besner 2009 in press).  As light does not induce any 
contamination and is not subject to wear and tear, the technique was naturally 
adopted for material processing.  An important application of PLA is pulsed laser 
deposition (PLD), which is the growth of thin films in vacuum or low background 
pressure.  In this process, material is removed from the surface of a target by 
irradiation with a laser beam and collected on a suitably positioned substrate.  Over 
the years, PLD have been used to deposit thin films a wide range of materials, 
including metals, semiconductors, superconductors, insulators, polymers and 
biological materials (Jackson 1994; Chrisey 2003). 
More recently, several research groups have investigated PLA for the generation of 
nanoparticles of a variety of materials in gaseous environment.  For example, Dolbec 
et al. deposited platinum nanoparticles onto a pyrolitic graphite and a silicon 
substrate (Dolbec 2004).  Mao et al. reported mechanical properties of nickel (Ni)  
nanocrystals which were deposited onto silica and sapphire thin films using pulsed 
laser deposition (Shan 2004). Steitz et al. fabricated silver nanoparticles of 
predetermined size and very high size uniformity using laser irradiation of large metal 
clusters (Bosbach 1999).  Kabashin et al. prepared thin films of photoluminescent 
silicon nanoparticles (Kabashin 2002).  As nanoparticles synthesized by PLA in 
gaseous environment tend to agglomerate irreversibly, the method is well adapted for 
the fabrication of thin films of the nanoparticles, but less so when dispersed 
nanoparticles (such as nanosuspensions in a liquid) are desired.  Laser fabrication of 
nanoparticles in liquid environment proved to be a much better alternative for the 
production of nanosuspensions.   
Laser fabrication of nanoparticles in liquids is a relatively recent, but rapidly growing 
research field (Barcikowski 2009). The approach encompasses two methods: laser 
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ablation and laser fragmentation in liquids. In laser ablation, first introduced in the 
early 1990s, a laser radiation is focused on a solid target immersed in a liquid, 
resulting in the ablation of the material and dispersion nanoparticles of the solid in the 
liquid (Figure 3.1 A). In laser fragmentation, on the other hand, the laser is focused 
on a stirring suspension of the material powder dispersed in a liquid in order to 
modify (usually to reduce) the size or the shape of the initial particles (Figure 3.1 B) 
(Sugimori 2000).  
 
 
Figure 3.1: (A) Typical experimental set-up for laser ablation at solid-liquid interface 
and (B) laser fragmentation; irradiation of of suspension by laser (Sugimori 2000).  
Laser fabrication in liquids can be applied universally with almost unlimited variety 
of materials (organic and inorganic alike – see sections 3.2 and 3.3 below) and liquid 
(A) (B) 
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matrices (Yang 2007; Barcikowski 2009). A stabilizing agent (eg. surfactants, salts 
and biocompatible molecules) can be incorporated in the liquid in order to control the 
size of the nanoparticles and improve the stability of the nanosuspension produced. 
Several types of lasers, with different wavelengths, average and peak output powers 
and pulse durations, are now available for the laser processing of materials.  The 
wavelength of the laser, relative to the absorption of the material, and power of the 
laser radiation are parameters strongly impacting on the amount of energy transferred 
to the material under treatment.  The duration of the laser pulse is also a determinant 
parameter in the ablation process.  Compared to nanosecond and longer pulses, 
ablation with femtosecond laser pulses provides two major advantages: (1) the 
reduction of the pulse energy which is necessary to induce ablation for fixed laser 
wavelength and focusing conditions and (2) a significant reduction or complete 
removal of heat-affected zones around the laser-treated zone (Yang 2007).  It follows 
therefore, that the energy is more effectively used to break physical bounds, thus 
limiting the fraction of energy dissipated in the form of heat that could be harmful to 
the material. 
In the following two sections, the laser fabrication of inorganic and organic 
nanosuspensions in liquids is briefly reviewed. The laser-based approach proposed in 
this thesis to produce drug nanosuspensions is described in section 3.5. 
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3.2 Fabrication of inorganic nanosuspensions  
Unique electronic, magnetic, optical and catalytic properties of metal (eg. Au, Ag, Pt, 
Co and Cu), metal oxide (FeO, ZnO and TiO2) and semiconductor (PbS, CdS, Ag2S 
and Si) nanoparticles offer great advantages for technological applications and for 
fundamental research (Katz 2004).  Inorganic nanoparticles are promising for 
application in electronics (Huang 2001), photonics (Law 2004), hierarchical 
biologically inspired nanocomposites (Fan 2000), biochemical sensing and imaging 
(Katz 2004) and drug delivery (Salem 2003).  For many years gold nanoparticles 
have been used as contrast agents in electron microscopy (Murphy 2005).  More 
recently gold and silver nanoparticles are being used in biological optical imaging 
and sensing applications (Eugenii 2004).  
Suspensions of inorganic nanoparticles are usually produced by wet-chemical 
reduction or decomposition of precursors (eg. metal salts, metal carbonyls and 
molecular precursors) (Masala 2004; Besner 2005).  These techniques use various 
chemical steps often involving non-biocompatible chemical products. Furthermore, 
impurities (including unreacted starting materials, excess reagents, and byproducts 
resulting from side reactions or degradation pathways) are present in nanoparticle 
samples and may have a significant impact on properties such as reactivity, stability 
and toxicity (Dahl 2007).  Laser fabrication in liquids offers an interesting alternative 
for the production of inorganic nanosuspensions in a clean, contamination-free 
environment, with minimal concentration of surface-active agents.  Moreover, when 
adequate ablation conditions are chosen, metastable materials, not easily attainable 
otherwise under ambient conditions, can be achieved (Yang 2007).  The variety of 
inorganic nanosuspensions obtained by laser ablation and fragmentation in liquids has 
been recently reviewed by Yang (Yang 2007). 
The ultrashort (femtosecond) pulse laser ablation provides drastically different results 
from that of the nanosecond laser.  When ablation by femtosecond laser near the 
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threshold was used to produce gold nanoparticles in deionized water, nanoparticle 
size of 4–5 nm in size were achieved, which is virtually impossible with nanosecond 
laser ablation.  However, the small size and low dispersion was compromised by a 
very slow production. When ablation efficiency was improved, the average size and 
size dispersion increased (Kabashin 2003).  
The focusing conditions of the femtosecond laser ablation process provides a mean of 
varying specific conditions which control the size of the particles and efficacy of the 
procedure (Sylvestre 2005).  By varying the position (noted as z position) of the 
target (substance to be ablated), with respect to the focal plane of the focusing 
objective it is possible to alter the radiation fluence, which is defined as the energy 
per surface area.  At sufficiently high laser fluences, a plasma in the liquid above the 
surface of the target is formed.  Plasma is ionized ‘gas’ and constitutes the fourth 
state of matter.  It may be formed by the highly energetic species ejected from the 
target, or by optical breakdown in water (formation of a plasma in water by nonlinear 
absoprtion of the high power laser pulse).  The localized plasma can reach extremely 
high temperatures and pressures and may further contribute to the ablation (and 
melting) of the target.  Furthermore, as a result of the vaporization of water 
surrounding the plasma, a cavitation bubble in liquid is formed which expands and 
then collapses.  This mechanical energy impacting on the surface of the taget is 
suggested as another possible ablation mechanism. For the ablation of gold in water, 
an intense plasma was associated with higher ablation efficiency but larger 
nanoparticles (Kabashin 2003; Sylvestre 2005). 
The addition of stabilizing agents in the liquid environment may profoundly alter the 
final size distributions of the nanoparticles and stability of the resulting 
nanosuspension during laser ablation. For example Mafuné et al. studied the 
formation and size control of silver nanoparticles by laser irradiation of a solid target 
in a solution of sodium dodecyl sulfate (SDS).  They found that laser irradiation of 
the metal immersed in liquid allows for stable suspensions to be provided (Mafuné 
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2000).  It was determined that the average diameter of the nanoparticles decreased as 
the concentration of SDS increased.  Biomolecules, such as CDs had a similar effect 
during the fabrication of gold by covering the gold nanoclusters obtained, and 
limiting their growth and interactions (Sylvestre 2004).  More recently, Besner et al. 
demonstrated the in situ functionalization of gold nanoparticles may be achieved 
during laser fragmentation in presence of different biocompatible polymers (Besner 
2009). 
Finally, laser ablation and fragmentation are traditionally used on their own. It was 
recently demonstrated that the successive application of ablation followed by 
fragmentation could be an interesting approach to produce narrowly dispersed 
contaminant-free nanosuspensions. Since gold nanoparticles produced by 
femtosecond (fs) laser ablation in deionized water at high power were relatively large 
(few tens of nanometers) and largely dispersed, a second step (fragmentation) was 
introduced in order to refine the size of the particle (Besner 2007).   Further treament 
with laser fragmentation for 2h led to reduced to a particle mean size of 20 ± 4 nm 
from an initial size of 54 ± 36 nm (Besner 2006).  Moreover, the fragmentation 
experiments performed on gold colloidal particles showed that the final size 
distribution is independent of the initial size and shape of the particles.  The latter 
depends on the radiation parameters (eg. power, focusing position and time of 
irradiation) and on the presence of chemical additives, suggesting that the final size of 
the nanoparticles depends on the chemical interaction of the fragmented species in 
solution.  It was also shown that fragmentation of gold nanoclusters (previously 
formed via ablation) improved the solution stability.  Gold nanoparticles produced by 
ablation only agglomerated within a few hours, but nanoparticles which were further 
subjected to laser fragmentation remained stable for several months.  Such stability of 
gold nanopartiles in the absence of chemical additives was never reported before, and 
so the two-step fs laser assisted method was established as a successful tool to 
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fabricate small sized stable gold nanoparticles in a chemically pure and contaminant 
free liquid environment (Besner 2007).  
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3.3 Fabrication of organic nanosuspensions 
The development of laser techniques for fabrication of inorganic nanoparticles has 
attracted attention to fabricate organic nanoparticles using the similar methods. 
Recently laser techniques have been explored for the fabrication of organic 
nanoparticles in suspension (Asahi 2008).  The preparation of organic nanoparticles, 
such as aromatic and dye molecules has drawn increasing attention due to their 
application as pigments, cosmetics and new materials for optical and electronic 
devices (Li 2003).  A laser fragmentation method for the preparation of organic 
nanoparticles was developed by Masuhara and coworkers (Masuhara 2003; 2004), in 
which a nanosecond (ns) laser was applied to micrometer sized vanadyl 
phthalocyanine (VOPc) dispersed in various solvents suspension to fabricate 
nanoparticles.   They discussed the formation process of the VOPc nanoparticles, and 
the dependence of laser power as well as the size and morphology of the 
nanoparticles (Yoshiaki 2003).  
The ns laser fragmentation method was also applied to quinadrone (QA, a red 
pigment) microcrystals in water. It was shown that the crystalline phase and size of 
the nanoparticles were controlled by the intensity and wavelength of the laser (Jeon 
2007).  The ns laser fragmentation method established was used to fabricate 
pentacene nanoparticles and colloidal fullerene (C60) nanoparticles in ethanol solution 
(Itaya 2006).  
In these publications, no accounts of degradation analyses nor complete physico-
chemical characterizations were reported.  Spectroscopy results suggested that 
degeneration and decomposition of C60 nanocrystals by laser irradiation are 
insignificant.  The authors concluded that there was sign of photodecomposition at 
higher powers, however they did not provide quantitative data on the extent of 
degradation nor information on the polymorphic state of the nanoparticles.  In another 
study, ns pulsed radiation was used for the production of 3,4,9,10-
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perylenetetracarboxylicdianhydride (PTCDA) nanoparticles (Hobley 2007). The 
production of PTCDA nanoparticles was accompanied by formation of polyyne and 
perylene byproducts in photothermal and multi-photonic processes respectively. Once 
again the degradation and polymorphic state of the nanoparticles was not thoroughly 
investigated.                                                                                                       
The work previously reported utilises a nanosecond laser for the fabrication of 
nanoparticles, but recently it has been shown that fs laser irraditon of an organic 
suspension produces smaller nanocrystals. Indeed, Masuhara et al. reported that 
Ti:sapphire fs laser irradiation of bulk VOPc suspended in water produced 
nanoparticles of smaller size and narrower distribution in comparison with that by 
nanosecond laser irradiation (Masuhara 2004).  However no polymorphic or 
degradation study was conducted to test the VOPc nanoparticles.  
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3.4  Fabrication of drug nanosuspensions   
As discussed in chapter 2, formulation of poorly water soluble drugs into 
nanosuspensions can be used to overcome dissolution and bioavailability issues. 
Considering that the synthesis of a variety of inorganic and organic nanosuspensions 
could be achieved by laser ablation and fragmentation in liquids (sections 3.2 and 
3.3), it is interesting to ask whether the methods could be used for the fabrication of 
drug nanosuspensions fabrication.  To date, only one group has reported the 
production of drug nanoparticles by laser irradiation, but the laser fabrication was 
carried in a gaseous rather than a liquid environment.  In their studies, PLA was used 
to break the intermolecular van der Waals force of consolidated phenytoin and 
indomethacin in order to generate drug nanoparticles with size below 20 nm (Nagare 
2004).  Laser ablation was performed with a ns pulsed laser, by varying power.  More 
recently, the same group employed PLA, again in a gaseous environment, to form 
nanostructured indomethacin-bovine serum albumin composites (Nagare 2006). 
Changes in the crystallinity of indomethacin and in the tridimensional structure of 
albumin were observed.  In both studies, the authors did not examine the 
dispersibility of the resulting nanoparticles in water.  As previously mentioned 
(section 3.1), the particles produced in a gaseous environment – eg. the absence of a 
dispersing medium and a stabilizing colloid/surfactant, are usually irreversibly 
agglomerated. Accordingly, the dispersion of the individual nanoparticles in an 
aqueous medium should be extremely difficult, if not impossible.   
 
 
 
  
 
59
3.5  Research proposal & Objectives 
The proposed project of this thesis aimed to investigate the use of the recently 
introduced methods of fs laser ablation and fragmentation in liquids to fabricate drug 
nanocrystals. The two-steps laser ablation/fragmentation approach previously applied 
to the fabrication of gold nanosuspensions were investigated. In the first laser 
ablation step, laser radiation was focused on a solid tablet of the drug immersed in an 
aqueous solution of a suitable surfactant, resulting in the ablation and dispersion of 
the product in the liquid (Figure 3.2).  The generated dispersion was subjected to a 
second laser (fragmentation) treatment in which a laser beam is used to irradiate and 
refined the particles size (Figure 3.3). Alternatively, this two-step approach was 
substituted by a single laser fragmentation method where the microcrystalline powder 
of the drug was directly dispersed in an appropriate aqueous medium and treated with 
the laser radiation. Sterically stabilized drug nanoparticles in a dispersed (non-
agglomerated) state were anticipated for all the proposed approaches, and therefore 
overcoming the redispersion problems associated with the PLA technique.  Compared 
to ns pulses, fs pulses offered the advantage of ablating materials with less energy, 
thus limiting the possible alteration of the produced drug nanocrystals.  Indeed, due to 
the extremely short laser pulse, the energy was more effectively used to break 
physical bounds, thus limiting the heat dissipation that could be harmful to the 
material (Yang 2007).  Furthermore, there are evidences that fs laser ablation and 
fragmentation in liquids of inorganic and organic result in smaller nanoparticles with 
narrower size distributions compared to the ns processes (sections 3.2 and 3.3). 
Therefore, we hypothesized that femtosecond laser ablation in an aqueous 
environment would prove as an efficient and non-destructive production process of 
drug nanocrystals. 
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Figure 3.2: (A) Illustration of the production of drug nanoparticles by femtosecond 
laser ablation; (B) Photography of a paclitaxel tablet immersed in a poloxamer 188 
aqueous solution and irradiated by a femtosecond laser 
 
 
 
 
                                                        
  
 
Figure 3.3: (A) Size distribution of drug nanoparticles produced by femtosecond laser 
ablation before (■) and after (●) the second laser treatment step; (B) illustration of the 
fragmentation process during the second laser treatment step. 
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The feasibility of the proposed approach was investigated on paclitaxel, a cytostatic 
agent.  Paclitaxel, a diterpinoid pseudoalkaloid is an important anticancer drug 
extracted from the bark of Western yew, Taxus brevifolia (Panchagnula 1998).  With 
a molecular weight of 853 Da and molecular formula C47H51NO14, paclitaxel is a 
promising anti-tumor agent with poor water solubity (0.3 μg/mL) (Figure 4.2)  
It is a white crystalline powder, highly lipophilic and insoluble in water, with a 
melting temperature of 216-217°C (Singla 2002). Paclitaxel is a microtubule- 
stabilizing agent, such that it binds to the β-subunit of microtubules preventing their 
depolymerisation. When bound to paclitaxel the microtubules are not only stable, but 
also dysfunctional, thereby leading to cell death (Panchagnula 1998).  Paclitaxel 
works as an efficient anti-cancer agent and is used to treat breast and ovarian cancer, 
but also has neoplastic activity against colon, head, non-small cell lung cancer and 
AIDS related Kaposi’s sarcoma (Singla 2002).   
To enhance its solubility, paclitaxel is currently formulated in a vehicle of 50:50 
blend of Cremophor EL (polyethoxylated castor oil) and ethanol and is known as 
Taxol®.  Side effects associated to Cremophor EL, such as hypersensitivity reactions, 
nephrotoxicty and neurotoxicity, labored breathing, lethargy and hypotension are 
experienced by patients receiving Taxol® chemotherapy (Soga 2005; Miele 2009). 
Efforts are being made to prepare a stable paclitaxel formulation devoid of 
Cremophor EL and ethanol with reduced toxicity.  Research groups in pharmaceutical 
sciences have made many efforts to enhance the solubitlity of paclitaxel, by 
employing formulation strategies discussed in chapter 1.  For instance, liposomes, 
polymeric micelles and nanoparticles have been developed as carrier systems to 
solubilize paclitaxel (Liggins 2001; Fonseca 2002; Soga 2005).  Other attempts 
include use of emulsions, cylcodextrin or prodrug formation (Singla 2002).  Recently 
in 2009, Abraxane®, a novel albumin bound 130 nm particle formulation of paclitaxel 
marketed by Abraxis Bioscience has been developed for adjuvant treatment of breast 
cancer. Nyman et al. have shown that weekly dosing of Abraxane® is safe and 
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generates minimum toxic effect with objective antitumor responses in partients 
previsouly exposed to paclitaxel (Nyman 2005).  
The specific objective sof this research project are outlined as the following: 
- Firstly, to determine the optimal fabrication conditions to generate water-
dispersed paclitaxel nanocrystals      (below 500 nm in size with low 
polydispersity) using the fs laser methodologies.  The ablation conditions were 
optimized (power, time and focusing position), and then the subsequent 
fragmentation method was studied as a function of laser power.  
- The second specific aim was to produce paclitaxel nanocrystals of uniform size 
distribution, with minimizing chemical degradation.  
- Thirdly, the impact of optimal fabrication conditions on the crystallinity and 
polymorphic state were examined on the finest nanocrystal paclitaxel formulation.   
 
The aims, methodology and results of this project are further discussed in chapter 4 
and 5. 
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4.1  Abstract 
This study investigated a novel femtosecond (fs) laser technique, previously used to 
generate fine inorganic nanoparticles in a biologically friendly environment, for the 
fabrication of paclitaxel nanocrystals in aqueous solution. Two distinct methods of 
this technology, ablation and fragmentation, have been investigated. The influence of 
laser power, focusing position and treatment time on the particle size, drug 
concentration and degradation was studied. Particle size and degradation were 
evaluated using dynamic light scattering and high performance liquid 
chromatography respectively. Morphology and chemical composition was 
correspondingly studied by scanning electron microscopy and Fourier-transform 
infrared spectroscopy. Differential scanning calorimetry and X-ray diffraction 
spectroscopy were used to evaluate the polymorphic state of the paclitaxel 
nanocrystals. Optimal laser conditions generated uniformly sized paclitaxel 
nanoparticles (<500 nm) with quantifiable degradation. The crystalline morphology 
of the drug was retained upon nanonization, but the anhydrous crystals were 
converted to a hydrated form, a phenomenon also observed during bead milling. 
These findings suggest that drug nanocrystals can be produced with fs laser 
technology using very little drug quantities, which may be an asset for preclinical 
evaluation of new drug candidates.  
 
KEYWORDS: nanotechnology, nanoparticles, paclitaxel, femtosecond laser, 
preclinical development, preformulation, cancer, physicochemical, calorimetry, X-ray 
powder diffraction, morphology. 
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4.2  Introduction 
Over the recent years, drug design has explored and developed new chemical species 
resulting in more complex molecules with higher hydrophobicities. It is estimated 
that 40% or more of active substances being identified through combinatorial 
screening programs are poorly water-soluble. Consequently, formulation of these 
drugs presents a major challenge to their clinical development (Rabinow 2004).  As a 
result of their very low aqueous solubility such drugs cannot be injected 
intravenously and/or often have low oral bioavailability. Classical methods to 
increase the solubility include micellar solubilization, complexation (eg. 
cyclodextrins) and use of organic solvents.  However, these approaches are limited in 
their success (Muller 2001).   A common strategy to enhance dissolution rate of a 
drug is to decrease the particle size and hence increase the surface area of the drug 
powder. Nanonization which involves formulating the drug powder as nanometer-
sized particles was developed to further improve drug absorption and allow the 
intravenous injection of insoluble drugs (Merisko-Liversidge 2003).  There exist 
several methods to produce drug nanoparticles, of which at least two are used 
commercially: NanoCrystal® technology (Elan) based on a mechanical process of wet 
milling and DissoCube® (SkyePharma), a high pressure homogenization technique 
(Muller 2001; Keck 2006).  Concerns are often raised regarding the quality and 
durability of the milling media used in manufacturing and possible contamination of 
the product following erosion of the grinding material. Disadvantages of the latter 
method are that prior to preparing the dispersion, the drug needs to be micronized and 
changes in drug crystallinity have also been reported (Muller 2001). 
Laser techniques have been used extensively for the production of metal (Sylvestre 
2004) and organic nanoparticles (Asahi 2008; Besner 2008). These methods consist 
in the irradiation of a solid target or irradiation of a stirring suspension (Nagare 2004; 
Besner 2008). The high energy from the laser breaks the macroparticles into 
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nanoparticles.  The production of nanoparticles using laser irradiation has proved to 
be a simple and versatile technique in which stable and contaminant free 
nanoparticles are generated and thus toxicity problems associated with conventional 
methods of nanofabrication are avoided (Sylvestre 2005; Besner 2008).  Previously, 
nanosecond (ns) laser fragmentation method, in which a laser beam is focused into a 
stirring organic microsuspension was developed for the preparation of vanadyl 
phthalocyanine (VOPc) and quinadrone nanoparticles in suspension (Tamaki 2002; 
Asahi 2008). More recently, this technique was explored to fabricate colloidal 
fullerene (C60) nanoparticles and 3,4,9,10-perylenetetracarboxylicdianhydride 
(PTCDA) nanoparticles (Hobley 2007; Asahi 2008).  These studies reported very 
little information on the degradation and on the polymorphic transformation of the 
organic material upon laser fragmentation. Furthermore, these organic nanoparticles 
fabricated were for applications in cosmetics and optical/electronic devices and not 
for drug delivery.  Only one group has reported the production of drug 
(Indomethacin) nanoparticles by ns laser technique (Nagare 2004), where laser 
ablation (irradiation of a solid target) was performed with a ns pulsed Nd:YAG laser 
in a dry environment – i.e. the absence of a dispersing medium and a stabilizing 
colloid/surfactant.  Some changes in the crystallinity of indomethacin were observed.  
Alternatively, femtosecond (fs) laser technology is more favourable than the ns laser 
because fs pulses offer the advantage of ablating materials with less energy, thus 
limiting the possible alteration of the ablated drugs nanocrystals.  Therefore, fs laser 
irradiation in liquid could prove as an efficient and non-destructive production 
process of drug nanocrystals. Additionally, performing fs laser ablation in an 
appropriate aqueous medium will generate sterically stabilized particles in a dispersed 
(non-agglomerated) state.  Not only has the fs laser recently proven to be effective to 
produce fine inorganic nanoparticles with narrow size distribution (Besner 2007; 
2008), but has confirmed to fabricate smaller sized particles than the ns laser strategy 
(Masuhara 2004).  
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Previously described to fabricate gold nanoparticles (Besner 2007), the novel fs laser 
technology investigated here is based upon two distinct methods: ablation and 
fragmentation.  The first consists of a laser beam focused onto a solid target 
immersed in a liquid, resulting in the ablation of the material and dispersion of the 
product into the liquid. The subsequent colloidal suspension is then subjected to a 
second laser treatment (fragmentation) in order to refine particle size, resulting in 
smaller and narrower size-distributed nanoparticles (Besner 2008). The presented 
work thoroughly explores the fabrication of drug nanocrystals by fs-laser 
ablation/fragmentation in aqueous media with an exclusive characterization and 
degradation examination of produced nanocrystals, and describes the influence of 
process parameters on the physicochemical characteristics of the drug. The model 
poorly soluble drug used is paclitaxel (Figure 4.2), an anticancer agent isolated from 
the bark of Taxus brevifolia. Paclitaxel is generally dissolved in a vehicle of 50:50 
Cremophor EL and ethanol blend, which is further diluted with normal saline before 
intravenous administration. The disadvantage of this formulation is that Cremophor 
EL causes severe adverse reactions (eg. hypertension reactions, nephrotoxicity and 
neurotoxicity) (Dordunoo 1996; Singla 2002). These side-effects can be substantially 
alleviated by formulating paclitaxel as a nanoparticulate formulation (Miele 2009). 
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4.3  Experimental 
4.3.1 Materials 
Poloxamer 188 was supplied by BASF (Mississauga, ON, Canada). Anhydrous 
paclitaxel (purity 99.2%) was purchased from Bioxel Pharma (Sainte-Foy, QC, 
Canada). Dihydrate paclitaxel was purchased from Guanyu Bio-Technology Co., 
(Xi'an, China). Diphenylhydantoin (DPH) which served as an internal standard and 
Baccatin III were obtained from Sigma-Aldrich (Oakville, ON). 7-Epipaclitaxel, 7-
epi-10-deacetylpaclitaxel and 10-deacetylpaclitaxel were purchased from 21CEC PX 
Pharm Ltd (East Sussex, UK).  Deionised water was generated using Millipore Milli-
Q system (Bedford, MA) and all other reagents were of analytical or HPLC grade. 
4.3.2 Methods 
 4.3.2.1 Preparation of paclitaxel tablet and suspension 
Pure drug tablets without excipients were prepared in a hydraulic press using 4-mm 
diameter punches. The applied pressure was 3.9 x 108 N/m2 (x 25 s). Paclitaxel 
suspensions (200 μg/mL) were prepared by adding paclitaxel powder to freshly 
prepared poloxamer 188 (8 mg/mL) aqueous solution. The suspension was sonicated 
(10 min) and stirred vigorously for several hours to obtain a homogenous sample. 
 4.3.2.2 Fs-laser treatment 
Fs-laser radiation was used to ablate a solid paclitaxel tablet placed at the bottom of a 
10-mL glass beaker filled with 3.5 mL of poloxamer 188 solution (8 mg/mL) (Figure 
4.1i). The tablet was held in place within a hole having the size of the tablet 
performed in a metal disk. The experiments were carried out using a Hurricane, 
Spectra Physics Ti:sapphire laser (Newport Corporation, Mountain View, CA), 
providing 120 fs pulses centered at 800 nm with a repetition rate of 1 kHz. The beam 
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was focused by an objective with the focal length of 7.5 cm.  The focusing radiation 
was moved (0.5 mm/s)  using a motorized stage to obtain identical surface conditions 
during the laser ablation process (Figure 4.1ii).  Different parameters were varied, 
such as the power of ablation (25 to 400 mW), treatment time (10 to 60 min) and 
different focusing conditions, i.e. z positions of 0, 1 and 1.5 mm (Figure 4.1iii). 
Further size refinement was carried out using laser fragmentation of the produced 
drug nanocrystal dispersion. The drug suspension was transferred into another glass 
vial and the laser was focused in the middle of the stirred solution (500 rpm) for 60 
min (Figure 4.1iv). Laser power was manipulated from 25 to 400 mW. 
Alternatively, single-step fragmentation (no prior ablation) was conducted using 
prepared paclitaxel suspension (200 μg/mL).  Paclitaxel suspension (2.5 mL) was 
added to a small cuvette with a stir bar, and fragmentation (500 rpm) for 60 min at 
powers ranging from 50 to 400 mW (Figure 4.1iv). 
 4.3.2.3 Paclitaxel assay  
The amount of paclitaxel and degradation products in suspension, after laser 
treatments were evaluated by high performance liquid chromatography (HPLC) 
assay. The sample suspension was first mixed with equal volume of acetonitrile in 
order to dissolve the particles.  After vortexing, the internal standard, DPH (50 
μg/mL) was added, and the sample was filtered through 0.2-µm nylon membrane. 
Injection volume was 70 µL. HPLC was performed using a Waters HPLC system 
(Waters, Missisauga, ON, Canada) with a C18 column (3.5 mm x 16 mm, dp = 3 
µm). The elution was performed using an isocratic mix of water and acetonitrile 3:2 
(v/v) for 26 min, continuing with a gradient acetonitrile and mix 0:100 to 43:57 
within 21 min, at an elution rate of 1.2 mL/min. UV detection was set at 227 nm and 
column temperature was maintained at 35°C. Prior to sampling, calibration curves for 
paclitaxel and all 4 degradation products (baccatin III, 7-epipaclitaxel, 7-epi-10-
deacetylpaclitaxel and 10-deacetylpaclitaxel) were established (linearity range 0.3 -
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200 μg/mL). The content of paclitaxel and degradation products (μg/mL) was 
calculated using their respective calibration curves. The % degradation corresponded 
to the sum of degradation products (μg/mL) divided by the sum of paclitaxel and total 
degradation products x 100. 
 4.3.2.4 Particle size analysis and zeta potential measurements    
The size of nanocrystals was determined by dynamic light scattering (DLS) using 
Malvern Zetasizer NanoSeries, with a detection angle of 173° (Malvern, 
Worcestershire, UK). Each measurement was performed on undiluted suspension in 
low volume disposable sizing cuvette at 25°C in triplicate. The CONTIN program 
was used to extract size distributions from the autocorrelation functions. The zeta 
potential of the nanocrsystals was measured by electrophoretic mobility using 
Zetasizer NanoSeries; samples were prepared by mixing 400 µL of nanocrystal 
suspension with 500 µL of MilliQ water and 100 µL of saline (0.9% NaCl in water). 
Each measurement was performed in disposable zeta cells at 25°C in triplicate. 
 4.3.2.5 Scanning electron microscopy 
Morphological evaluation of the optimal paclitaxel nanocrystals was conducted by 
scanning electron microscopy (SEM). The nanosuspension fabricated by 
fragmentation was centrifuged to remove the excess surfactant. A drop of suspension 
was placed on a silicon substrate and dried overnight in a dessicator under vacuum. 
The sample was observed with a FE-MEB S-4700 field-emission scanning electron 
microscope (Hitachi, Tokyo, Japan). Paclitaxel control sample (non-fragmented) was 
prepared by adding pure paclitaxel drug powder to poloxamer 188 solution, sonicated 
(10 min) and stirred for several hours, but not subjected to laser treatment.  
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 4.3.2.6 Thermal Analyses 
For thermogravimetric analysis (TGA) and differential scanning calorimetry (DSC), 
the nanocrystals and control samples were prepared without poloxamer 188, in order 
to avoid signal interference from the polymer which degraded before the melting 
point of paclitaxel. TGA of the anhydrous paclitaxel, dihydrate paclitaxel, 
nanocrystals and water-exposed non-fragmented drug was performed with a TA 
Instruments TGA 2950 system (TA Instruments, New Castle, DE). Approximately 3 
mg of the paclitaxel sample was weighed in a platinum pan and heated to 700°C at a 
rate of 10°C/min under nitrogen purge. Thermal properties were obtained by DSC, 
TA Instruments DSC Q200 system, (TA Instruments, New Castle, DE). Samples of 
2-3 mg were placed and sealed in Tzero pinhole pans and analysed at a heating rate of 
50°C/min. High heating rate was used in order to avoid decomposition of the drug in 
the DSC furnace. 
 4.3.2.7 Spectroscopic Analyses 
Paclitaxel samples were analyzed by Fourier transform infrared spectroscopy (FTIR) 
for chemical composition and by X-ray diffraction (XRD) for crystallinity.  Prior to 
FTIR and XRD analysis, the control sample (raw paclitaxel suspended in poloxamer 
188 by sonication and stirring) and the laser fragmented nanocrystals were both 
cleaned by ultracentrifugation, and then lyophilized. Firstly, the samples were 
centrifuged for 15 min at 10,600 x g. The sedimented particles were washed with 
MilliQ water, re-suspended and centrifuged twice more to remove the residual 
poloxamer 188 and then lyophilized for 72 h. FTIR and XRD spectra were obtained 
for the lyophilized nanocrystals and control sample (non-fragmented), the raw 
anhydrous and dihydrate paclitaxel samples. FTIR analysis, with a resolution of 4  
cm-1, was performed with a Bio-Rad Excalibur Series spectrometer, FTS3000 (Bio-
rad Laboratories, Randolph, MA) using the potassium bromide (KBr) pellet 
technique. Each 150 mg pellet contained 2 mg of the paclitaxel sample. XRD spectra 
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were obtained with an X’Pert X-ray PANAlytical diffractometer (PANalytical Inc, 
Montreal, QC, Canada) using the grazing angle method in which the X-ray source 
was fixed at ω = 2°. Samples of 10-15 mg were used. The x-ray source was CuKα (50 
kV 40 mA). The 2θ range scanned was 5 to 50° at a rate of 0.02 °2θ/s. 
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4.4  Results & Discussion 
In the first part of this work, fs-laser ablation followed by subsequent fragmentation 
was explored. The ablation process was investigated as a function of power (25 to 
400 mW), focusing position (z = 0, 1 and 1.5 mm) and ablation time (20 to 60 min). 
Upon completion of the ablation process, the sample was collected and analyzed by 
HPLC for paclitaxel concentration and degradation products. Figure 4.3 (top) shows 
the concentration of paclitaxel particles produced after ablation as a function of laser 
power for 3 focusing positions.  At z positions of 1 and 1.5 mm, increasing the power 
from 25 to 400 mW resulted in a higher concentration of the suspended paclitaxel 
particles. Ablation was also more important at z position of 1.5 than 1 mm.  In all 
cases, degradation was relatively low but greater at z = 1.5 (ca. 2%).  Ablation at the 
surface of the tablet (z = 0 mm) generated the least degradation but also the least 
concentrated paclitaxel suspensions, thus indicating that ablation on the surface of the 
tablet was not an efficient method to produce particles.  It has been reported that 
ablation of z = 0 mm generates a plasma (partially ionized matter, containing a 
portion of free electrons) which readily absorbs part of the laser radiation, leaving 
less energy for the ablation of the target (Sylvestre 2005).  The size of the particles 
was independent of the power since particles ranging from 800-3000 nm were 
observed at all powers (data not shown).  As ablation at z = 1.5 mm generated the 
largest degradation, subsequent experiments were carried out at z = 1 mm.  The effect 
of time of ablation was then assessed at a power of 150 mW.  As illustrated in Figure 
4.3 (bottom), the amount of paclitaxel particles produced increased as a function of 
exposure time and reached a plateau between 20 and 40 min (~ 50 μg/mL).  After 20 
min ablation, the suspension became relatively turbid, thereby decreasing the ablation 
efficiency. The turbidity of the suspension caused the laser beam to be scattered, 
thereby reducing the energy available to ablate the tablet. Ablation for over 20 min 
also generated more degradation (data not shown). The optimal ablation condition 
was selected as: z =1 mm, treatment time of 20 min and power of 150 mW.  Next, a 
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stock suspension prepared via optimal ablation was subjected to fragmentation from 
25 to 400 mW.  This second laser treatment did refine the mean diameter of the 
particles; particles as small as 50 nm were obtained, however the particle size 
distribution remained considerably large (Table 4.2).  Degradation also increased 
with laser power, reaching important levels (>4%) above 150 mW.  The zeta potential 
was almost neutral and did not change with fragmentation conditions. 
As the overall efficiency of the two step ablation/fragmentation process was limited 
by the amount of drug ablated in the initial step, an alternative strategy based upon 
fragmentation alone was explored.  A paclitaxel suspension (~ 200 μg/mL) was 
prepared directly by adding the drug powder to the poloxamer 188 solution. The 
suspension was fragmented at powers ranging from 50-400 mW, and size and 
degradation were measured (Table 4.3).  As the power increased, smaller particles 
with acceptable polydispersities (PDI ~ 0.3) were obtained, however higher 
degradation was observed (up to 23% at 400 mW).  This trend in particle size was 
reported in other studies involved in the production of C60 and VOPc nanoparticles 
using a ns-laser fragmentation method (Tamaki 2002; Asahi 2008), suggesting that 
higher laser power provides greater energy to fragment particles, thus smaller 
nanocrystals are obtained.  This single step fragmentation process yielded a smaller 
size distribution in comparison to the ablation/fragmentation method. The 
morphology assessment by SEM confirmed that significant nanonization occurred 
during laser fragmentation.  The original needle-like shape was retained upon 
fragmentation at 400 mw for 60 min, and size was reduced from micro- to 
nanoparticles (Figure 4.4).  In previous studies, it was demonstrated that laser 
irradiation of VOPc microcrystals dispersed in solvent changed the morphology of 
the initial crystals (Tamaki 2002).  Such morphological change was not observed 
when paclitaxel was fragmented using the fs laser technique. 
Following the size and degradation examination of the paclitaxel particles, further 
characterization was carried to evaluate the hydration and crystalline states of the 
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drug upon laser fragmentation.  The fs-laser generated nanoparticles were compared 
to anhydrous paclitaxel, dihydrate paclitaxel and a non-fragmented water exposed 
sample which was fabricated by suspending the anhydrous drug in the aqueous 
solution followed by lyophilization.  
FTIR spectroscopy was used to characterize the hydration state of the various 
paclitaxel samples (Figure 4.5). The peak shapes of anhydrous paclitaxel and the 
water-exposed non-fragmented paclitaxel were similar at 3500 cm-1 and 1700 cm-1. 
At these wavenumbers the dihydrate paclitaxel and the laser fragmented sample 
displayed broadened and less defined peaks, suggesting hydration of the drug upon 
laser fragmentation.  A general trend was observed: the peaks became less defined 
(eg. loss of doublet peak around 1700 cm-1) and broadened as the sample becomes 
more hydrated. This phenomenon of doublet to singlet peaks upon hydration of 
paclitaxel has been reported before (Pyo 2007).  
As expected, DSC analysis showed that the anhydrous paclitaxel and water-exposed 
non-fragmented sample exhibited a sharp melting point at ca. 225°C (Liggins 1997). 
This melting endotherm was also observed in the dihydrate paclitaxel sample, but 
was not seen in the laser fragmented sample (Figure 4.6). DSC analysis depicted the 
degradation of the fragmented sample at temperatures above 220°C, this correlated 
with the TGA analysis which demonstrated that degradation occurred at a lower 
temperature in comparison to the other paclitaxel samples (Figure 4.S1). Dihydrate 
paclitaxel exhibited a broad endotherm from approximately 50-125°C corresponding 
to water evaporation (Gi 2004). A similar endotherm, but less broad was observed in 
the fragmented sample, indicating that this sample displayed a hydrated nature. 
Additionally, a significant endothermic peak at 170°C (relevant to a solid-solid 
transition), was observed in the dihydrate paclitaxel and to a lesser extent in the laser 
fragmented sample (Gi 2004).  
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In order to obtain more insight into the possible polymorphic transformation 
occurring upon fs-laser fragmentation, XRD analysis was performed on the drug 
samples (Figure 4.7). Anhydrous paclitaxel exhibited characteristic XRD peaks at 2θ 
= 5.6°, 9.1°, 10.4°, 12.7° and 21.1° (Liggins 1997).  Anhydrous and dihydrate 
paclitaxel demonstrated different XRD patterns, and thus there was a polymorphic 
transformation upon hydration of anhydrous paclitaxel (Liggins 1997; Pyo 2007). 
Five new peaks (6.2, 9.8, 11.2, 13.3 and 16.7), which were all absent in the anhydrous 
paclitaxel appeared in the water-exposed control, laser-fragmented and dihydrate 
samples, thus suggesting partial hydration of paclitaxel.  As the anhydrous paclitaxel 
was suspended in water it became slightly hydrated as evidenced by the apparition of 
peaks characteristic of the dihydrate form. As fragmentation was performed, the 
hydration of the drug augmented and thus displayed similar XRD patterns to 
dihydrate paclitaxel (Figure 4.7).  Moreover, the paclitaxel suspension (700-800 nm 
sized particles) prepared by bead-milling displayed similar features to the laser 
fragmented sample suggesting that nanonization of paclitaxel in water transforms 
anhydrous drug into the hydrated state (Fig 4.7 and Fig 4 S2).  
By compiling the calorimetry and spectroscopy results, it appears that the anhydrous 
drug underwent crystalline change into dihydrate form after fs laser treatment in 
water. The slight differences between the laser fragmented and the dihydrate samples 
may be due to the presence of degradation products or small size of the nanocrystals. 
These two paclitaxel forms both exhibit needle shaped crystal habit (Liggins 1997). 
In previous work reporting the laser fragmentation of organic suspensions, 
quantitative degradation studies were not performed (Hobley 2007; Sugiyama 2009).   
Sugiyama et al. assessed the photoproducts of C60 by 13C NMR. They revealed that 
no appreciable photoproduct was formed under specific ns-laser irradiation 
conditions, although decomposition of C60 was induced at a higher fluence (Sugiyama 
2009).  Hobley et al. used the similar pulsed ns-laser technique to fabricate PTCDA 
nanoparticles (Hobley 2007). Byproducts of PTCDA were indentified but no 
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quantitative degradation study was conducted. In the present work, nanoparticles of a 
complex drug molecule were prepared by fs laser method and the production of 
degradation products was monitored. The fs laser treatment was previously shown to 
generate smaller particles than ns-laser (Masuhara 2004).  However, as can be seen in 
Tables 4.2 and 4.3, the fabrication of particles of less than 1000 nm was associated 
with significant degradation of paclitaxel.  The latter is a labile molecule (Jiaher 
2008; Jiaher 2009) and therefore it can be expected that chemically less complex and 
more stable drugs would be better suited for nanonization by fs laser treatment.  In 
order to decrease the degradation process, fragmentation was performed under an 
inert atmosphere (argon), in the presence of antioxidants (L-cysteine) or with other 
stabilizing agents (polysorbate 80, polyvinylpyrrolidone). However, these approaches 
proved unsuccessful (data not shown).  
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4.5  Conclusion 
In this work, fs laser irradiation was explored for the fabrication of paclitaxel 
nanocrystals. Narrowly-dispersed paclitaxel nanoparticles of approximately 400 nm 
were obtained by single-step fragmentation.  However they were associated with 
significant degradation. The polymorphic transformation of paclitaxel into the 
dihydrate state is not associated with the fs laser conditions, but rather is 
characteristic of any nanonization method performed in water. Paclitaxel is perhaps 
not the best drug candidate for this nanonization technique, nevertheless work in 
progress for other hydrophobic drugs, eg. megesterol acetate, suggests that fs laser 
fragmentation may be an alternative route for the production of nanoparticles of other 
poorly water soluble and less sensitive drugs (Sylvestre 2009). Though several 
studies have reported use of laser technology for the development of organic 
nanoparticles, this is the first investigation where a novel fs-laser fragmentation 
technique is used for the fabrication of paclitaxel nanocrystals in aqueous medium, 
and in which the nanocrystals have been fully characterised. A current limitation of 
the fs-technique as presented here is that the efficiency of the process is limited by the 
increase in turbidity of the suspension as more particles are produced. However, this 
problem could be easily solved by implementing a continuous flow system, which 
may also eventually lead to lower degradation of the drug.  This work may translate 
into successful future avenues for the production of drug nanocrystals for an array of 
pathologies including cancer and infectious diseases. In addition, this fs-laser 
technology presented here may be valuable in the preclinical development. In the pre-
formulation and late discovery stage, compound availability is scarce and thus 
examining numerous formulation approaches is difficult (Van Eerdenbrugh 2008; 
2009). Using the fs-laser technology on minute amounts of drug (μg) to fabricate 
nanoparticles may be advantageous as an in vivo screening approach. If the 
nanocrystal formulation appears to be promising (eg. displays good bioavailability), 
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then more conventional techniques may be applied for the production of greater 
amounts of nanocrystals without degradation. 
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Figure 4.1: Representation of fs-laser ablation (top) and fragmentation (bottom) 
methods.  
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Figure 4.2: Chemical Structure of paclitaxel (5β,20-epoxy-1,2α,4,7β,13α-
hexahydroxytax-11-en-9-one 4,10-diacetate2-benzoate 13-ester with (2R,3S)-N-
benzoyl-3-phenyllisoserine). (Singla 2002) 
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Figure 4.3 (Top) : Paclitaxel concentration of the suspensions prepared by fs-laser 
ablation at focusing positions of z = 0 mm (squares), 1 (circles) and 1.5 (triangles), at 
power ranging from 25 to 400 mW. Mean ± SD (n=3). (Bottom) : Paclitaxel 
concentration of the colloidal suspensions prepared by fs-laser ablation at focusing 
positions z = 1, 150 mW, and time ranging from 10 to 60 min. Mean ± SD (n=3). 
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Fig 4.4: Scanning electron micrographs of (right) water-exposed non fragmented 
paclitaxel and (left) laser  fragmented paclitaxel nanocrystals (400 mW, 60 min).  
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Fig 4.5 :FTIR spectra of anhydrous paclitaxel (d), water exposed non-fragmented 
paclitaxel (c), laser fragmented  nanocrystals (b) and dihydrate paclitaxel (a) 
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Figure 4.6: DSC thermograph of anhydrous paclitaxel (a), water exposed non-
fragmented paclitaxel b) laser fragmented (400 mW, 60 min) nanocrystals (c) and 
dihydrate paclitaxel (d).  
 
 
 
a 
b 
c d 
  
 
90
 
 
Figure 4.7: XRD analysis of anhydrous paclitaxel (d), water exposed non-fragmented 
paclitaxel (c), laser fragmented (400 mW, 60 min) paclitaxel nanocrystals (b) and 
dihydrate paclitaxel (a).  
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Table 4.1: Degradation of the paclitaxel colloidal suspensions generated by ablation at 
three focusing conditions. Mean ± SD (n=3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Degradation (%) 
Power (mW) z = 0 mm z =1 mm z = 1.5 mm 
25 0.7 ± 1 0.3 ± 0.2 1.8 ± 1.7 
50 0.3 ± 0.4 0.5 ± 0.3 2.9 ± 1.9 
100 0.5 ± 0.5 1.0 ± 0.5 2.2 ± 0.7 
150 0.8 ± 0.4 0.8 ± 0.1 2.3 ± 1.3 
250 0.8 ± 0.3 1.1 ± 0.2 2.8 ± 1.1 
400 0.8 ± 0.4 1.8 ± 0.7 2.1 ±  0.5 
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Table 4.2: Chemical degradation, size distribution and surface charge of paclitaxel 
suspensions prepared by two-step fs-laser ablation and fragmentation. Mean ± SD 
(n=3). 
Power (mW) [PTX] (μg/mL) Degradation (%) Size (nm) PDI Zeta potential (mV) 
0 37.3 ± 3 1.6 ± 1 2700 ± 800 0.9 ± 0.2 -6.0 ± 3.0 
25 34.5 ± 4 4.0 ± 1 2000 ± 500 0.7 ±0.2 -5.6 ± 0.4 
50 32.3 ± 3 3.3 ± 2 2200 ± 600 0.9 ± 0.1 -6.8 ± 0.5 
100 33.2 ± 2 2.8 ± 1 1500 ± 450 0.7 ± 0.3 -6.2 ± 0.3 
150 30.8 ± 1 3.8 ± 2 1100 ± 400 0.3 ± 0.2 -4.4  ± 0.2 
250 14.1 ± 2 9.7 ± 1 300 ± 100 0.6 ± 0.2 -5.8  ± 0.9 
400 10.3 ± 1 8.0 ± 3 50 ± 15 0.7 ± 0.2 -1.0 ±  0.6 
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Table 4.3: Chemical degradation and size distribution of paclitaxel particles obtained 
by fragmentation (60 min) Mean ± SD (n=3) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Power (mW) Size (nm) PDI  Degradation (%) 
50 3000 ± 160 0.29 ± 0.20 1.2 ± 0.14 
100 1100 ± 70 0.34 ± 0.07 8.3 ± 0.41 
150 800 ± 30 0.32 ± 0.05 12.6 ± 1.3 
250 600 ± 50 0.31 ± 0.04 17. 1 ± 1.7 
400 400 ± 60 0.29 ± 0.07 23 .1 ± 2.0 
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Supporting Information 
 
             
           
      
 
Figure 4.S1: TGA thermograph of paclitaxel anhydrous powder (a), water exposed 
non-fragmented paclitaxel  (b) laser fragmented (400 mW, 60 min) nanocrystals (c) 
and dihydrate paclitaxel (d). Weight percent is expressed in solid line and derivative 
weight percent is expressed as dashed line 
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mill-PTX 
2H2OPTX 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. S2. XRD analysis of milled paclitaxel (mill-PTX),  dihydrate paclitaxel 
(2H2OPTX) and anhydrous paclitaxel (PTX). 
 
The milled paclitaxel sample was prepared by bead milling. 0.5%(w/w) of paclitaxel 
was suspended in a 0.125% (w/w) Poloxamer 707 solution in ultrapure water. This 
suspension was added to a glass vessel with zirconium oxide beads (3 mm diameter) and 
placed on a roller mill. After 4h of agitation at 220 rpm, the beads were separated and size of 
the drug particles was measured by DLS. The suspension was washed by centrifugation and 
lyophilized before XRD analysis.  
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Table 4.S1 : XRD peaks (angle 2θ) comparison of anhydrous paclitaxel, water-
exposed paclitaxel, laser fragmented nanocrystals and dihydrate paclitaxel. 
Raw PTX Control PTX Fragmented PTX Dihydrate PTX 
5.73 5.45 5.44 5.43 
  6.27 6.25 6.25 
    
9.11 9.13   
  9.87 9.85 9.87 
10.27   
  11.25 11.17 11.13 
11.43   
12.63 12.69 12.75 12.71 
  13.89 13.83 13.83 
14.11   
14.77   
15.87 15.79 15.67 15.55 
  16.71 16.71 16.61 
17.37 17.25   
18.21 18.19   
18.97 18.97   
  19.25 19.11 
19.75 19.67 19.67 19.57 
  20.59 20.45 
21.15   
21.39 21.43 21.51 21.39 
22.21 22.25 22.45 22.41 
  22.95 22.95 
  23.63 23.51 
  24.21 24.19 24.17 
25.55 25.39 25.11 
  26.71 26.79 26.65 
27.11 27.35 27.31 
28.99 28.81 28.89 28.35 
  29.09 28.75 
30.25 29.01 
  31.23 29.19 
  31.13 
  34.33   34.33 
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The general objective of this research project has been accomplished such that 
uniformly small sized paclitaxel nanocrystals have been generated using the 
femtosecond laser technology previously employed for gold nanoparticles (Besner 
2008).  Ideally the fabrication of drug nanocrystals with little chemical degradation 
and polymorphic transformation were anticipated. However, laser fragmentation at 
high powers generated hydrated paclitaxel nanocrystals with considerable 
degradation (Table 4.2 and 4.3). 
Firstly the aim to produce paclitaxel nanocrystals with diameters below 500 nm and 
low polydispersity (<0.3) was achieved by optimizing femtosecond laser methods. It 
was shown that laser ablation of the paclitaxel tablet did not generate monodisperse 
particles, and generally the sizes of 800 to 1500 nm were obtained. Though the two 
step (ablation and subsequent fragmentation) method produced desired nanocrystal 
size, the degradation of the drug was significant. Finally the single step fragmentation 
generated nanocrystals below the size of 500 nm at high powers.  
Secondly, the objective of studying the impact of fabrication conditions on chemical 
degradation was achieved. The effect of ablation and fragmentation power on the 
chemical integrity of paclitaxel was monitored by an optimized HPLC assay. Even 
though high laser powers generated small sized nanocrystals, the integrity of the drug 
was compromised such that higher degradation was observed.  
Thirdly, the study of the impact of fabrication conditions on morphology and 
polymorphic state was realized. It was established that femtosecond laser 
fragmentation of anhydrous paclitaxel at high power, generated hydrated nanocrystals 
with crystalline character. 
Before the production and evaluation of the drug nanocrystals, an HPLC assay was 
standardized (Appendix III). In the following sections, the key aspects of this 
research project: the optimization of ablation and fragmentation methods, attempt to 
decrease degradation and finally the characterisation of the optimal nanocrystals are 
discussed in further detail. 
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5. 1  Optimization of laser ablation procedure 
The parameters investigated to obtain optimal laser ablation conditions included 
power, focusing condition (z position) and time. By changing the laser power it was 
possible to alter the energy provided to ablate the tablet, thus affecting the ablation 
rate, the plasma formation over the surface and the cavitation dynamics in water.  The 
variation of the position of the tablet with respect to the focal plane of the focusing 
objective (z position) allowed for the irradiation fluence to be varied (section 3.2) 
influencing the size and degradation of the drug particles. In addition, the time of 
ablation was varied to determine the optimal duration of ablation for the least 
degraded and smallest sized particles.  
Firstly, femtosecond laser ablation was studied as a function of power and focusing 
conditions. All three focusing positions (z = 0, 1 and 1.5 mm), demonstrated that as 
the power increased from 25 to 400 mW, the concentration of the paclitaxel 
nanocrystals in suspension also increased (Figure 4.3 top).  At higher powers, 
stronger ablation occurred resulting in greater amounts of drug particles being 
generated in suspension. With this increase in drug amount, an increase in 
degradation was also observed (data not shown).  This could be explained as follows, 
as femtosecond radiation acted on a solid target (paclitaxel tablet), the energy was 
absorbed by the target. Then, several picoseconds after the laser pulse, the radiation-
related ablation of material occured, resulting in the ejection of small clusters 
(Sylvestre 2005).  The nano-clusters coalesced during their subsequent cooling in the 
ambient medium, forming particles in the nanometer size range. Moreover, as the 
laser power increased, the water layer just above the target surface strongly absorbed 
the radiation (refered to as optical breakdown), and became ionized forming a hot 
plasma. Heat transfer from the plasma to the target and shock wave production 
generated by the plasma expansion etched the surface and caused the ejection of large 
nanoclusters. This mechanism was previsously proposed for the fabrication of gold 
nanoparticle by femtosecond laser ablation in water.  In addition, it was previously 
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suggested that the formation and collapse of the cavitation bubble (section 3.2) also 
lead to ablation of the gold surface. In this project, the ablation of paclitaxel tablet 
probably took place in the similar manner. 
The size of the particles was independent of the laser power, since particles ranging 
from 800-1500 nm were observed. Previously femtosecond laser ablation of a gold 
target in suspension generated smaller nanoparticles at lower laser fluences 
(Kabashin, 2003). This was not the case for the generation of paclitaxel nanocrystals 
and the difference may be due to the friability of the drug tablet.  
To better understand the ablation process, the surface of the tablets ablated at a low 
and high power were analysed by SEM (Figure 5.1).  The crater formed at low power 
(50 mW) displayed fine lines depicting the path of the laser beam, whereas ablation at 
higher power (250 mW) displayed a uniform circle on the surface of the tablet, 
showing that the ablated area increased with the laser fluence (power), thus resulting 
in overlap at the ablated regions from one line to the next. Augmentation of the 
ablated area with laser power was also observed for the production of gold 
nanoparticles using the same femtosecond laser technique and was attributed to 
greater heating effects at higher powers (Kabashin, 2003). 
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Figure 5.1: SEM images of craters formed with ablation ( z = 1 mm, 20 min) on the 
surface of paclitaxel tablet at 50 mW (Left) and 250 mW (Right).  
 
Ablation at position z = 1.5 mm produced higher concentrated drug suspensions 
because of the enlargement of the irradiation spot on the tablet surface (Figure 4.1iii).  
Previously, for the ablation of gold nanoparticles by fs laser ablation, it was shown 
that an enlargement of irradiation spot size due to change in focusing condition (z 
position) led to lower amount ablated as a result of reduced laser fluence.  However, 
in our study, it was observed that as z position increased, a larger irradiation spot led 
to more drug being ablated and thus more particles in suspension (Figure 4.3 top). 
This result suggested that ablation of paclitaxel can be achieved at lower fluences 
than gold. This was perhaps not surprising considering that only intermolecular 
interactions between the paclitaxel molecules need to be broken, rather than the 
stronger bonds between the gold atoms, for ablation to occur.  Moreover, the 
paclitaxel tablet was much more friable than gold, which made it more prone to 
mechanical erosion due to cavitation effects.  Ablation at z = 0 mm generated the 
least amount of paclitaxel nanoparticles as well as the least degradation (Table 4.1).  
The low amounts of drug ablated at the surface may be due to the smaller irradiation 
spot size ablating the tablet, and to a significant laser energy loss due to absorption in 
water (optical breakdown) above the drug tablet, a phenomenon observed during 
ablation of gold (Sylvestre 2005). 
Ablation at 150 mW and z = 1 mm resulted in the highest amount of drug 
concentration with the least amount of degradation (Table 4.2).  By focusing the laser 
beam at 1 mm into the tablets, the time of ablation was evaluated as a function of 
power (Figure 4.3 bottom).  Indeed 20 min was the optimal time of ablation because 
it provided the highest amount of drug with the least degradation. It was observed 
that the paclitaxel concentration reached a plateau after 20 min of ablation. This may 
be explained by the fact that as more particles were generated the suspension became 
opaque, thereby scattering the laser beam and reducing the intensity of the laser 
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energy reaching the tablet surface. Due to the decreased energy, ablation of the tablet 
was inefficient after 20 min; therefore the concentration of the drug remained 
constant.  Though it was suspected that ablation efficiency decreased after 20 min, 
there was an increase in degradation as time of ablation increased. The particles in 
suspension (produced via ablation) interacted with the laser energy more frequently 
and thus degradation increased as a function of time.  
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5.2 Optimization of fragmentation (following ablation)  
Once the ablation process was optimized at z = 1 mm, for 20 min at 150 mW, further 
size refinement of the drug particles was carried by fragmentation. A stock colloidal 
suspension was prepared via ablation and from this suspension; samples were 
withdrawn and fragmented at individual power ranging from 25-400 mW.  Large 
nanocrystals generated by laser ablation interacted more strongly with the radiation 
and fragmented, resulting in a narrower and smaller size distribution. As 
fragmentation power increased, smaller sized particles were obtained, but degradation 
increased once again (data not shown).  
The effect of the concentration and type of surfactant on the size and degradation of 
paclitaxel was studied (Table 5.1).  Ablation was performed at the optimal conditions 
described above and fragmentation was performed at 150 mW for 60 min. Increasing 
the poloxamer 188 (Pluronic F68®) concentration had no significant effect on the 
final size and degradation of the nanoparticles. Ablation and fragmentation in Solutol 
HS-15 (polyethylene glycol 660 hydroxysterate) generated particles with much lower 
degradation however very large particles were obtained.  It was suspected that the 
larger particles had less interaction with the laser irradiation and thus degraded to a 
lesser extent.  
Table 5.1: Degradation and size analysis of paclitaxel particles generated by ablation 
and fragmentation in two different surfactants at various concentrations n=1. 
 
 
 
 
 
 
 
 
        
Surfactant 
Concentration (μM) 
% Degradation Final size distribution 
Ablation Fragmentation Size (nm) PDI 
Pluronic F68         
0.238 10.4 14.3 1000 ± 100 0.2 ± 0.06 
0.952 9.5 11.1 980 ± 10 0.4 ± 0.07 
1.785 8.9 10.3 950 ± 50 0.5 ± 0.04 
Solutol HS-15 
0.238 4.1 7.32 5400 ± 200 0.4 ± 0.1 
0.952 6.9 8.6 4600 ± 550 0.5 ± 0.2 
1.785 6.5 8.2 2900 ± 250 0.3 ± 0.04 
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5. 3   Optimization of single-step fragmentation strategy 
The two-step femtosecond laser strategy: (ablation followed by fragmentation) was 
inconvenient in generating small sized paclitaxel nanoparticles ( ≤ 500 nm) with low 
degradation ( ≤ 2%).  In addition, the concentration of paclitaxel in suspension was 
limited by the amount of drug ablated in the first step. Hence, an alternative 
fragmentation single step fragmentation method was introduced, in which a paclitaxel 
suspension was prepared directly by adding drug to a surfactant solution. Poloxamer 
188 was selected as a suitable surfactant because it proved to fabricate smaller 
particles in comparison to other surfactants (Table 5.1). Four different drug 
suspensions were prepared and subjected to fragmentation at 400 mW. The size and 
degradation of the fragmented suspension were evaluated to determine which 
concentration provided homogenous nanocrystals (Table 5.2).  The least concentrated 
suspension (177 μg/mL) demonstrated the least degradation and the smallest sized 
nanoparticles. The higher concentrated paclitaxel suspensions were not homogenous, 
therefore all further experimentation was performed using paclitaxel suspensions with 
a concentration less than 200 μg/mL. 
 
Table 5.2: Degradation and size analysis of fragmented paclitaxel suspension, n=1 
[Paclitaxel] 
(μg/mL) % Degradation 
Size 
(nm) PdI 
177.6 0.2 311 ± 6 0.6 ± 0.05 
312.5 1.1 288 ± 21 0.5 ± 0.05 
793.4 0.9 321 ± 20 0.5 ± 0.02 
642.7 1.1 272 ± 2.8 0.4 ± 0.03 
 
 
Paclitaxel suspensions (≈ 200 μg/mL) were fragmented for 60 min at powers ranging 
from 50-400 mW (Table 4.3). At lower power, microcrystals (≈ 3 μm) were obtained 
with acceptable degradation (≈ 1%). As the laser power was increased, smaller 
particles were generated, resulting in nanocrystals (400 nm) with substantial 
degradation (≈ 23 %).  Though this single step fragmentation process yielded good 
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size distribution, the degradation was relatively high and therefore various strategies 
were investigated to reduce the oxidation.  
Suspecting that the degradation may be due to oxidation, fragmentation studies were 
conducted using anti-oxident (L-cysteine), however no change in degradation was 
observed.  Further, fragmentation was performed under inert conditions using argon 
in a closed system.  The paclitaxel suspensions were bubbled under argon for 10 min 
prior to fragmentation, and then kept in the inert environment during the laser 
treatment.  Once again, no difference in degradation was observed, suggesting that 
degradation of paclitaxel was not a result of oxidation induced by reactive oxygen 
species present in solution.  Suspecting that the degradation products might be of a 
different size than the paclitaxel nanocrystals or in solution, size exclusion 
chromatography was performed. Several fractions were collected and assayed via 
HPLC for degradation products and DLS for size.  The degradation products were not 
separable from paclitaxel, and so it was concluded that fragmentation at high power 
produced nanocrystals with degradation on the surface of the drug crystal.   
The possible explanation for the generation of paclitaxel degradation upon high 
power laser fragmentation was based upon the formation of a localized hot plasma in 
the aqueous environment.  Indeed, during laser fragmentation, optical breakdown 
(generation of a plasma accompanied by cavitation effects) in water occurred in a 
small volume near the focal point of the lense.  As the power increased, the intensity 
of the plasma increased, thereby increasing the thermal and mechanical effects 
(Sylvestre 2005; Besner 2006).  It is likely that this thermal and mechanical energy 
(cavitation, also suggested as a size reduction mechanism in homogenization, see 
Chapter 2) produced in the water through optical breakdown is transferred to the 
nearby drug particles thereby fragmenting them into nanoparticles.  In the process, 
the thermal energy could however induce chemical degradation of the drug. 
Consequently, as the laser power was increased, smaller particles were obtained due 
to increased fragmentation efficiency, but larger degradation was observed (Table 
4.3).  
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5.4   Optimization of fragmentation in larger volume 
As characterization tests required a substantial amount of sample (eg. 15 mg for 
XRD) a “scale up” process for the generation of paclitaxel nanocrystals was 
attempted. Previously laser fragmentation was carried in volume of 2.5 mL, 
consisting of 500 μg of paclitaxel. To obtain a minimum of 20 mg of dried paclitaxel 
nanoparticles for characterization studies, fragmentation (400 mW) in a 10 mL 
volume was employed. The larger volume fragmentation generated large sized 
particles with much lower degradation in comparison to the traditional method (Table 
5.3).  In order to refine the size, an additional hour of fragmentation was performed 
which reduced particle size to 1800 nm, however degradation of the drug increased. 
As the volume of fragmentation increased, the likelihood of the particles interacting 
with the laser decreased.  Even though the energy of the system remained constant at 
400 mW, the larger volume caused the fragmentation efficiency to decrease, thus 
generating larger sized particles. Since the particles were not being fragmented as 
much due to decreased contact with the laser beam, less degradation took place. 
 
Table 5.3: Fragmentation process in large volume (10 mL) at 400 mW, n=1. 
Time Volume (ml) % degradation Size (nm) PDI 
0 0 0 17000 ± 3000 0.4 ± 0.2 
1 h 2.5 25.1 400 ± 60 0.3 0 ± 0.07 
1 h 10 2.3 2200 ± 60 0.3 ± 0.08 
2 h 10 4.4 1800 ± 200 0.4 ± 0.3 
 
By these preliminary results, it was decided that a larger volume fragmentation 
method was not a successful strategy to fabricate nanoparticles of 400 nm, therefore 
several small batches of 2.5 mL were produced in order to produce over 20 mg of 
lyophilized paclitaxel nanorystals. 
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5.5   Characterization of paclitaxel nanocrystals 
 
After several attempts of reducing the degradation of paclitaxel nanoparticles, 
characterization was carried on the optimized formulation (400 nm in size, 23 % 
degradation). The nanocrystals remained stable and did not agglomerate for four 
weeks. SEM analysis confirmed the significant size reduction and showed that the 
needle-like morphology of the drug remained intact after fragmentation at high 
powers (Figure 4.4).  The needle-like morphology signified that the sizes obtained by 
DLS (where spherical particles are assumed) reported in this thesis should be 
interpreted with care. While the sizes reported cannot reflect the exact dimensions of 
the ‘needles’, they can be used to differentiate the size reduction efficiency of the 
different laser processing conditions tested.  
Since the fragmentation process was carried in water, it was suspected that there may 
be some hydration of the drug, therefore dihydrate paclitaxel was investigated in 
parallel to the paclitaxel nanocrystals.  DSC analysis demonstrated that the laser-
treated paclitaxel nanocrystals displayed a different polymorphic state than the pure 
anhydrous paclitaxel, since the characteristic melting endotherm at 225°C was absent 
(Figure 4.6).  The thermal events of the laser treated sample were similar to the ones 
of dihydrate paclitaxel.  XRD analysis further confirmed the fact that indeed 
femtosecond laser fragmentation at high powers generated hydrated paclitaxel (Figure 
4.7).  Many of the characteristic paclitaxel XRD peaks disappeared in the laser-
treated sample, suggesting that the polymorphic state changed (Table 4.S1).  The 
laser treated sample displayed peaks analogous XRD peaks to the dihydrate paclitxel, 
thus confirming the fact that anhydrous drug was transformed into a hydrated form 
upon femtosecond laser treatment in water. Considering that the transformation of 
anhydrous paclitaxel into the hydrated form in presence of water is documented 
(Liggins 1997) and that partial hydration of the drug was observed in absence of laser 
treatment (Chapter 4), it is likely that any wet nanonization method would result in 
the hydrated form of the drug, although experimental confirmation would be required.  
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By analyzing the polymorphic state of the laser treated nanocrystals it was concluded 
that anhydrous pacitaxel became hydrated upon femtosecond laser fragmentation at 
high powers. The degree of hydration was questionable because there were 
differences in the polymorphic analysis of dihydrate and laser treated samples. The 
slight dissimilarity between the two samples may be due to the extensive degradation 
of the drug. Paclitaxel is a very sensitive compound and is susceptible to solvolysis 
(Dordunoo 1996). It degrades easily at high temperatures and thus suspected to be an 
inappropriate candidate for femtosecond laser fragmentation.  
Another limitation of this technique was that the amount of drug nanocrystals 
produced was low. This could be resolved by employing a flow through system, in 
which the drug nanocrystals are transferred to another vessel for collection once the 
desirable size is obtained. At the same time, more drug suspension is added to the 
stirring fragmentation vial for nanocrystal production. By simultaneously removing 
the drug nanocrystals and adding new suspension to be fragmented, there is a faster 
generation of nanocrystals. An optimized flow through system may possibly help 
reduce degradation because the produced nanocrystals will be removed from the 
system, and avoid further laser treatment and subsequent degradation. 
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To our knowledge, this was the first study in which active pharmaceutical ingredient 
was used for the fabrication of nanocrystals using a femtosecond laser technology, 
and complete characterization was conducted. Small sized and stable paclitaxel 
nanocrystals were produced in a contamination-free aqueous environment. The 
limitation of this technique was the considerable degradation of paclitaxel, however 
this could have been reduced by substituting with less sensitive drugs. It was 
suspected that degradation of the drug was a consequence of the thermal effects 
generated by the plasma at high powers. Further investigation on the generation of 
plasma would have confirmed this theory. 
Despite the degradation observed in this study, the femtosecond laser fragmentation 
could be an efficient tool for preclinical evaluation of many drug candidates. Early 
identification of formulation strategies help guide drug molecules through preclinical 
development. Often times limited amounts of the compound are available therefore 
formulation approaches using minute amounts of drug are necessary for evaluation. 
The conventional methods used to fabricate drug nanocrystals typically require large 
amounts of drug. Therefore the femtosecond laser fragmentation may be utilized to 
investigate the formulation of the drug as nanocrystals, using scarce amounts (μg to 
mg). If the screening tests (eg. bioavailability study) prove the nanocrystal 
formulation to be successful in enhancing the solubility of the drug, then 
conventional (eg. Nanocrystal® technology by Elan) methods may be applied to 
produce greater amounts of drug nanocrystals (Gao 2008).   
Other projects in the lab; fragmentation of less sensitive drugs (eg. megesterol 
acetate) suggests that fs laser fragmentation may be an alternative route for the 
production of nanoparticles of other poorly water soluble and less sensitive drugs 
(Sylvestre 2009).  Suggestions to improve this project involve the nanonization of 
several less sensitive drugs using fs laser fabrication. The oral bioavailability, 
pharmacokinetics and anticancer activity of the reformulated drugs would then be 
investigated.   In addition, it would be interesting to design a continuous flow cell to 
enhance the efficiency of the fs-laser fragmentation method for the fabrication of 
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nanocrystals. Upon successful achievement, this work may translate into successful 
future avenues for the production of drug nanocrystals for an array of pathologies 
including cancer and infectious diseases. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
118
References 
 
Besner, S., Kabashin A. V., et al. (2006). Fragmentation of colloidal nanoparticles by 
femtosecond laser-induced supercontinuum generation. Appl Phys Lett 89: 233122-3. 
 
Besner, S.,. Winnik, F. et al (2008). Ultrafast laser based “green” synthesis of non-
toxic nanoparticles in aqueous solutions. Appl Phys A: Mater Sci 93(4): 955-959. 
 
Gao, L., Zhang D., et al. (2008). Drug nanocrystals for the formulation of poorly 
soluble drugs and its application as a potential drug delivery system. J Nanopart Res 
10: 845-862. 
 
Sylvestre, J.-P. (2009). Fabrication of dispersed megestrol acetate nanocrystals by 
laser fragmentation in water. 2009 AAPS Annual Meeting and Exposition, Los 
Angelos   
 
Sylvestre, J. P., Meunier, M. et al (2004). Stabilization and size control of gold 
nanoparticles during laser ablation in aqueous cyclodextrins. J Am Chem Soc 126: 
7176-7177. 
  
 
 
 
i
Appendix I: Mononuclear phagocyte system 
The mononuclear phagocyte system (MPS) (also referred to as the reticuloendothelial 
system) is a network of macrophages and their precursors in the body's tissues, which is 
concentrated in the bone marrow, liver, spleen, and lymph nodes. Macrophages are large 
phagocytic cells that clear the blood, lymph and tissues of particles (eg. bacteria, cell debris 
etc..).  
 
Hume, D. A., Ross, I. L. et al. (2002). The mononuclear phagocyte system revisited. J 
Leukoc Biol 72: 621-627 
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Appendix II : Degradation products of paclitaxel 
 
Bacattin                                                                                                    10‐deacetyl paclitaxel 
 
                                                 
 
 
 
 
7‐epi paclitaxel 
 
 
10‐deacetyl‐7‐epi paclitaxel 
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Appendix III: HPLC Assay  
The chemical integrity of paclitaxel was monitored by HPLC using a C18 reverse 
phase column and an eluent mixture containing acetonitrile and water using 
procedures previously validated for paclitaxel (www.uspnf.com). Calibration curves 
for paclitaxel and the degradation products; Baccatin III (Bac), 10-Deacetylpaclitaxel 
(DPTX), 10-Deacetyl-7-epipaclitaxel (DEPTX), 7-Epipaclitaxel (EPTX) were 
established prior to the testing of nanocrystals generated by the femtosecond laser. 
The products were assayed according to the tests described in the United States 
Pharmacopoeia respective monographies. The paclitaxel content (μg/mL) was 
calculated based upon an established calibration curve [y = mx +b], where y is the 
area of paclitaxel divided by the area of DPH, and x is the concentration (μg/mL) of 
paclitaxel in the sample. The concentration of each degradation product was 
calculated in the similar manner using calibration curves. The sum of degradation 
products (μg/mL) was divided by the sum of paclitaxel and total degradation, and 
then multiplied by 100 to obtain the percent degradation. Below are the 
chromatographic profiles of paclitaxel and the degradation products. 
 
 
 
 
Figure A3:  HPLC assay of paclitaxel (top) and degradation products (bottom). 
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The impurity of paclitaxel was calculated as 0.5 %, which was in agreement of the 
manufacture’s certificate of analysis. The additional peaks observed in the 
chromatograph of the degradation products results from minor impurities which were 
present in the drug as purchased.  
The calibration curves were carried every month to ensure the adequate calculation of 
the degradation in the fragmented samples. 
 
